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Abstract 
Estrogen stimulation through the estrogen nuclear hormone receptor is major 
risk factor for the development of breast cancer (BC). Any changes in the properties 
of nuclear hormone receptor (NHR) pathways can lead to alterations in hormonal 
effects on tissues, making inherited genetic variants affecting NHR pathways 
potentially able to alter estrogen’s effect on BC susceptibility. Nuclear hormone 
receptor co-activators (NCoAs), that facilitate the transcriptional regulation by NHRs 
and activate gene expression, are one of many co-enzymes in the NHR pathway to 
assist signal transmission in gene expression. Therefore, potentially functional single 
nucleotide polymorphisms (SNP) in the coding sequence of an NCoA may alter 
NHR mediated gene expression. This study was conducted to investigate the 
relationship between three potentially functional SNPs located in NCoAs 1 and 3 and 
BC susceptibility. This is a case-control study of 276 Caucasian Australian women 
with BC and controls matched for age and ethnicity. All samples were genotyped 
using PCR and high resolution melting methods. The data were analysed by using 
Chi-square and linear regression methods to assess the effects of the polymorphisms 
and hormonal risk factors. My data analysis using Chi-square showed no significant 
association between the SNPs in this study with the risk of BC; however linear 
regression analysis showed that BMI appears as a predictor risk for BC only when 
the SNPs are included in the model, indicating potential interaction of these SNPs 
and peripheral estrogen production in adipose tissue, making BMI an interesting 
factor for further research. Gaining an understanding of how these SNPs interact with 
estrogenic effects on BC risk could lead us to develop more effective guidelines for 
BC screening and a basis for research into their effect on BC treatments based on 
anti-estrogen hormones. Thus my research may be a first step to understanding this 
impact on both treatment and susceptibility.  
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Chapter 1: Introduction 
 
1.1 CANCER 
 
Cancer arises from the accumulation of somatic mutations in a normal cell 
leading to formation of neoplasm with an uncontrolled proliferation of mutated cells 
(Albertson et al., 2003; Blanpain, 2013; Hanahan et al., 2000). A stem cell also can 
lead to carcinogenesis through defects in its maturation. The normal development of 
a mammary stem cell into a mature breast cell begins with differentiation into a 
progenitor cell and progresses stepwise to a mature breast tissue cell, for example: 
myoepithelial cells; ductal epithelial cells or; alveolar cells, which are under 
hormonal control (Hennighausen et al., 2001). Prior to or during the process of 
differentiating into a mature breast cell, it may develop the characteristics of a cancer 
stem cell which retains the self-renewing characteristic of a stem cell (Daniel et al., 
1971) leading to differentiation of its daughter cells into non-tumorigenic cancer 
cells (Dontu et al., 2003). Cancer is a disease that has been known about since 
antiquity. Between the 3rd and the 4th centuries BC, the Greeks provided the origin 
for the word cancer to describe the disease which is derived from the Greek word 
“karkinos” (Sudhakar, 2009). 
Cancer, a cellular disease, can strike almost any tissue though in adults these 
are most frequently epithelial tissues involving the breast, lungs, prostate, skin, and 
others (Ferlay et al., 2010).  A tumour is made up of many different cancer cell types 
that work together heterogeneously to maintain the survival of the cancer tumour, 
often resembling a distorted form of the original tissue type (Neve et al., 2006). 
The transformation of a normal tissue cell into a cancer cell is due to genetic 
instability (Blanpain, 2013). Through mutation to key genes, a cell acquires a new 
level of self-control and independence from body signals. This gives the cell 
characteristics that increase its rate of replication, evade attack by the immune 
system, cause it to live longer, and assure the tumour development (Hanahan et al., 
2000). Many of these same characteristics are used by a normal cell to maintain 
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equilibrium of healthy tissue cells (Pietras et al., 2010). Cancer cells are capable of 
overpowering the usual controls on these characteristics and controlling them; as a 
result cancer cells will go on to form an appropriate cell microenvironment to 
maintain their survival (Hanahan et al., 2011). 
In the last two decades, cancer research studies have established cancer cell’s 
altered characteristics, including maintaining uncontrolled proliferation, fighting the 
action of tumour suppressors, resisting cell death, ability to activate invasion and 
metastasis, inducing oncogenesis, activating replicative immortality, avoiding 
immune destruction, and reprograming the energy metabolism (Hanahan et al., 
2011). 
 
1.1.1 Maintaining proliferation 
 
Growth factors transmit mitogenic signals through binding with cell-surface 
receptors. These stimuli activate the intracellular kinase cascade followed by the 
activation of more proteins. This cascade activation is tied to the control of many 
cellular responses such as survival, differentiation, growth, apoptosis, metabolism 
and proliferation (Mochizuki et al., 2007). A healthy tissue controls the production of 
growth signalling to ensure the equilibrium of cell number and to maintain a normal 
tissue structure. Cancer cells acquire the ability to alter mitogenic signalling in many 
ways, by inducing production of growth factors themselves or stimulating nearby 
normal cells to produce growth factor, ending up with an uncontrolled cell division 
and growth (Dutta et al., 2012). Direct mutation to cell surface receptors to a 
permanently activated form is also common, freeing the cell from the need for 
external signals altogether (Mochizuki et al., 2007). 
 
1.1.2 Fighting growth suppressors 
 
Retinoblastoma (RB) and TP53 proteins are described as the “guardians of the 
genome” for their role in protecting the genome from mutation. These genes play an 
important role as tumour suppressors through controlling the cell cycle (Burkhart et 
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al., 2008). Any form of DNA damage activates these growth suppressor genes, 
leading to repression of cell division for DNA repair or induction of apoptosis (cell 
suicide) for the death and elimination of damaged cells, to maintain overall cellular 
and genetic stability in the body (Macleod et al., 1996; Tsai et al., 1998). For 
maintaining their growth and survival, cancer cells alter the function of growth 
suppressors through deletion or repression of expression to stop any signals that 
affect its uncontrolled division (Hanahan et al., 2011). 
 
1.1.3 Resisting cell death 
 
Apoptosis, a normal process to maintain tissue homeostasis, is induced by cell 
stress or by the effect of anticancer therapy (Tesniere et al., 2008). This programmed 
cell death is triggered by two activation pathways: the intrinsic (mitochondrial 
pathway), where specific death signals typically arising within the cell induce the 
release of mitochondrial associated proteins, leading to apoptosis and; the extrinsic 
(death receptor pathway), where the activation of transmembrane death cell receptors 
directly stimulates self destructive proteins such as caspases, leading to apoptosis 
(Elmore, 2007; Putcha et al., 2002). Each pathway leads to apoptosis but both are 
linked by the BH3-only protein, which is upregulated by TP53(Ashida et al., 2011; 
Hanahan et al., 2011). BH3-only plays a main role in the activation of some caspases 
(a family of cystenine proteases) and two main pro-apoptotic triggering proteins (Bax 
and Bak) (Garg et al., 2012). Cancer cells fight apoptosis in many different ways, by 
blocking TP53 tumour suppressor genes, triggering the production of anti-apoptotic 
regulators, increasing the production of survival signals or by supressing the 
proapoptotic triggering proteins (Ashida et al., 2011; Hanahan et al., 2011). 
 
1.1.4 Inducing angiogenesis 
 
The main function of blood vessels is to transport the nutrients and oxygen to 
the cells and evacuate metabolic wastes and carbon dioxide; this plays an important 
role in sustaining cell survival in normal tissue (Grützkau et al., 1998; Hanahan et 
al., 2011). Angiogenesis, the formation of blood vessels, requires the signalling from 
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several pro-angiogenic growth factors such as vascular endothelial growth factor 
(VEGF) (Boesiger et al., 1998; Ribatti et al., 2004). Cancer cells require nutrients 
and other factors like normal tissue to keep growing, and their need triggers the 
process of angiogenesis by overexpressing these pro-angiogenic growth factors 
(Ribatti et al., 2012). In tumour angiogenesis, the blood vessels, in addition to their 
main function of supplying food and evacuating wastes, enable tumour expansion 
and metastasis into nearby tissues by providing access to the open liquid of the blood 
supply and motive force from the heart (Ribatti et al., 1999; Vrancken et al., 2012). 
 
1.1.5 Ability to activate invasion and metastasis 
 
Cancer cells are able to escape from their primary site and push into new areas 
adjacent to them or be disseminated into distant organs, processes called invasion 
and metastasis, respectively (Harris, 2002). The processes of these two abilities are 
poorly understood; however they resemble wound healing processes and require 
many steps involving changes in cell-cell and cell-extracellular matrix attachments 
(Yamaguchi et al., 2005). Cancer cells in situ are surrounded by an intact basement 
cell membrane which makes the first step of invasion to induce protein matrix 
destruction, followed by intravasation, the invasion of cancer cells through the basal 
membrane (Egeblad et al., 2010). Many cancer cells stop there, but others will go on 
to the process of metastasis. The metastasising cells can enter lymph nodes through 
damaged basement membranes, leading to a lymphatic spread of cancer cells to 
distant sites, and then they may enter blood circulation or even bypass the lymphatic 
system and directly enter blood circulation (Gupta et al., 2006). Following entry into 
the blood or lymphatic system, the process is reversed by extravasation and invasion 
of cancer cells through circulatory system into other organs where the cancer cells 
maintain their survival and commence growth anew, leading to colonisation in 
foreign tissue (Hanahan et al., 2011; Pietras et al., 2010). 
 
 
 
 
Chapter 1: Introduction 5 
 
1.1.6 Activating replicative immortality 
 
Normal tissues have a finite replicative ability regulated by telomeres that are 
found at the end of chromosomes; the presence of large telomeres enhances cell 
proliferation, resistance to apoptosis, and repair of DNA damage (Kim, 1997; 
Maciejowski et al., 2017). In normal cells, telomere length shortens after each round 
of growth, and multiple replications lead to growth arrest or cell death. Immortality, 
one of main mechanisms that allow cancer cells to achieve growth into macroscopic 
tumours, is provided by the activation of telomerase, an enzyme that increases 
telomere length (Cairney et al., 2008; Meeker et al., 2002). Cancer cells activate 
replicative immortality by overexpressing the telomerase enzyme to protect the ends 
of the chromosomes from degradation following rapid replication and allow the cell 
to continue this unlimited cell division. Without this enzyme, the chromosomes of 
cancer cells would erode rapidly until the point when vital genes were damaged, 
preventing any possible further replication (Cairney et al., 2008). 
. 
1.1.7 Reprograming energy metabolism 
 
One of the main factors of cell survival is the cell’s energy metabolism which 
undergoes aerobic and anaerobic phases (Gonzalez et al., 2012; Mayevsky, 2009). 
To maintain uncontrolled proliferation a cancer cell should not only alter cellular 
proliferation but also deregulate cellular energy metabolism in order to use all this 
produced energy as a fuel for its cell growth. The abnormal characteristics of cancer 
cell energy consumption were first observed by Otto Warburg, who observed that 
cancer cells reprogram their metabolic energy use, focusing mainly on glucose 
metabolism by the glycolysis process (Balding et al., 2014). This followed the 
observation in many studies that a huge amount of glucose consumption occurred in 
many tumours. A main step of this reprograming is that cancer cells upregulate 
glucose transporters, such as glucose transporter 1 (GLUT1), to increase the amount 
of glucose in the cell. Even though focusing cell energy production through 
glycolysis decreases the amount of adenosine triphosphate (ATP) production per unit 
of glucose than full aerobic respiration, cancer cells can divert glycolic intermediates 
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to many pathways, including for the manufacture of new cells (Diaz-Ruiz et al., 
2011). 
 
1.1.8 Avoiding immune destruction 
 
Immune surveillance is an essential process that protects human health by 
preventing the formation of tumours in human body. An active immune system, 
including macrophages, CD8+ T cells, and NK cells, continuously monitor, recognize 
and eliminate the majority of cancer cells before they can form a tumour mass 
(Hanahan et al., 2011).  However, solid tumours that reach clinical attention manage 
to hide and avoid the immune system detection by using cancer immunoediting 
processes which include three key phases, elimination, equilibrium and escape (Dunn 
et al., 2004). Once the immune system recognizes cancer cells, the elimination phase 
takes place, but unfortunately not all cancer cells are eliminated. The immune system 
instead controls the growth and proliferation of those not completely eliminated 
transformed cells, which is the equilibrium phase. This is followed by the escape 
phase, where those cancer cells that are not effectively detected and destroyed by 
immune system escape to continue to divide and grow (Dunn et al., 2004; Nolte et 
al., 2012). Cancer cells that successfully navigate these phases acquire the ability to 
evade immune destruction (Dunn et al., 2004; Nolte et al., 2012). 
  
1.1.9 Genome instability and mutation 
 
With every cell division, the human genome is under a high risk of developing 
a mutation, which is normally repaired by genome maintenance mechanisms, which 
repairs any identified defective DNA, lowering the overall rates of mutation (Deng, 
2006). Genome maintenance mechanisms, referred as the “care taker”, operate 
through tumour suppressor genes, which are involved in detection of the DNA 
damage, repression of growth, repair damage directly, and inactivation or 
interception of mutagenic molecules (Duesberg et al., 2003; Wang et al., 2008). In 
cancers, there are multiple alterations in the genome, which serve as the foundation 
for many oncogenic processes. Cancer cells typically have increased rates of 
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mutation through inactivating or supressing the genomic maintenance mechanisms 
(Hoeijmakers, 2001). In addition, the uncontrolled proliferation and survival of 
cancer cells also has the effect of increasing the mutation since one of the functions 
of the genomic maintenance mechanisms is to monitor genomic integrity and order 
any genetically damaged cells to die through apoptosis (Hoeijmakers, 2001). 
Analysis of cancer cell genomes reveals that genetic instability increases during 
tumour progression (Negrini et al., 2010; Ried et al., 2000). 
 
1.1.10 Tumour promoting inflammation 
 
Despite the important role of the immune system in protecting human body 
from various diseases, sometimes it has a dark side in the presence of cancer, and 
even before cancer, by promoting cancer development (Erez et al., 2010). During 
cancer, the presence of inflammation, which is a sign of immune system protection, 
provides the microenvironment with many factors like growth factors, survival 
factors and pro-angiogenesis factors that acts as helping aid for the cancer cells to 
maintain their growth and survival (Bissell et al., 2001). In addition to that, the 
tumour associated inflammation can also release some chemicals into the 
microenvironment of the cancer cells that may lead to gene mutations which favour 
the acceleration and formation of tumours (Grivennikov et al., 2010; Hanahan et al., 
2011).  
 
 
1.2 SIGNIFICANCE, SCOPE AND DEFINITION 
 
Breast Cancer (BC) is a chronic disease that has a significant impact on the 
morbidity and mortality of those who suffer it (Moreno, 2013). Treatment failure is a 
significant problem in breast cancer, and there is no reliable way to cure the disease 
at this time. In addition, it is the most common cancer affecting women worldwide 
(Kusminsky, 2015). This research was conducted to reveal some of the missing 
pieces of the breast cancer puzzle, in order to have a clearer view of how the disease 
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works and increase my general understanding of breast cancer, and some of the 
factors involved in its initiation. 
The struggle with breast cancer is not only with the disease itself; it has an 
impact in the human dimension, including grief and social impacts on patients, 
families and friends; it has significant impacts on society, increasing numbers for 
mortality and morbidity, causing lost creativity and productivity; it impacts on 
government, through costs for diagnosis, treatment and research; and it impacts on 
the scientist, trying to search for results to better patient care (Mariotto et al., 2011; 
Sherwell-Cabello et al., 2017).  
The personal impact on breast cancer patients is significant, and it can often be 
a greater struggle than the disease itself (Judge et al., 2017). Adding to their 
physiological distress, breast cancer patients are trying to cope with a totally new 
lifestyle that adds sources of psychological pain. These new lifestyle changes are due 
to body changes, side effects of treatment, and coping emotionally with these factors 
requires specific models of survivorship care (Judge et al., 2017). 
Families and friends are also affected when seeing their loved ones suffer 
emotional and physical pain, and sometimes this long, painful ride ends with the loss 
of their loved one. From the perspective of a person who went through all this when 
family members were diagnosed with breast cancer, I have direct experience of how 
devastating and heartbreaking this can be, attesting that new knowledge is what is 
needed. The impact of breast cancer on society is due the increasing numbers of 
individuals suffering mortality and morbidity. BC has the highest incidence of any 
kind of cancer in women excluding skin cancer (Desantis et al., 2014). In 2017, 
breast cancer is predicted to be the most common type of new cancer in women in 
Australia (AIHW, 2017). 
There is also a huge impact on the government through economic pressures, 
due to the costs for the diagnosis and treatment of the disease, as well as for breast 
cancer research (Judge et al., 2017). This does not mention the time and skills 
consumption, where many skilled scientists and medical staff could spend their 
efforts focusing on other diseases if we were able to reduce the need for them to 
assist breast cancer patients. Costs to government also return in the form of lost tax 
revenue, as patients and families reduce their capacity to work and contribute to the 
wider economy (Judge et al., 2017). In 2009 the health expenditure on breast cancer 
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in Australia was $411 million, making breast cancer the most expensive cancer 
amongst Australian women. This amount was split between breast cancer screening, 
hospital inpatient cost, pharmaceutical prescriptions and hospital costs (AIHW, 
2013). The estimates of lifetime patient costs of breast cancer in the US were $16.5 
billion in 2010, and this figure is estimated to rise up to $20.5 billion in 2020 
(Mariotto et al., 2011). 
Breast cancer dominates the second place for the most common cancer 
amongst women in United States after skin cancer; and is the second highest cause of 
death among all types of cancers after lung cancer (Desantis et al., 2014). The 
situation is similar in Australia, but while breast cancer is projected to be the most 
common cause of cancer in women in 2017, it is only the second most common 
cause of death due to cancer in women after lung cancer (AIHW, 2017). Combining 
the knowledge from the studies done in the past decade, I can conclude that the main 
risks of breast cancer are a result of the interaction between both genetic variation 
and environmental lifestyle factors (Robson et al., 2010). A very small proportion of 
breast cancer cases are hereditary and most of these arise from a gene mutation in the 
most famous two genes associated with breast cancer, BRCA1 and BRCA2 (King et 
al., 2003). However, the greater proportion of breast cancer cases arise from more 
subtle genetic predispositions, filtering through lifestyle and environmental factors, 
including age, menopausal status, number of children, time spent breast feeding, 
smoking status, body mass index (BMI), physical activity, diet and others 
(EHBCCG, 2003; Helmrich et al., 1983). Many of these risks are relatively high in 
developed countries, which is an explanation for the higher numbers of breast cancer 
seen within (ACS, accessed 2015). 
Breast cancer comes along with some symptoms which complicate 
management of the disease; because not all of them happen in all breast cancer 
patients and presentation can also depend on the stage and the aggressiveness of the 
individual breast cancer. Symptoms include the appearance of a lump or a mass in 
the breast, which is usually painless, in addition to breast swelling leading to visible 
deformity as the cancer progresses (Andersen, 2011; Burgess et al., 2001). Sores 
may appear on the breast skin in advanced breast cancer that may result in bleeding 
or infection (Burgess et al., 2001). Very late stages of breast cancer are associated 
with cancer metastasis to axillary lymph nodes and distant organs. Early stage breast 
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cancers may involve local lymph node spread, if any (Alitalo et al., 2005; Gupta et 
al., 2006). 
A common first step for the detection of breast cancer is physical examination 
by patients themselves or clinical examination by a trained health worker to detect 
the tumour mass. In addition, mammography screening is becoming more efficient in 
developed countries compared to older screening methods and is contributing to 
earlier detection of breast cancers before they can develop increased malignancy 
(Aydiner et al., 2016). Unfortunately, sometimes screening is not enough, especially 
where some cancers are poorly detected by mammography due to unusual patterns of 
growth that are not indicative of cancer (Mainiero et al., 2016). In that case, a biopsy 
is the alternative step to check whether an unusual screening result is a cancer or not. 
Earlier diagnosis through screening means many varieties of effective treatment will 
be available, giving clinicians and patients a choice of treatments with fewer side 
effects (Aydiner et al., 2016; Mainiero et al., 2016). 
Taking into consideration the tumour size, breast cancer stage, its 
aggressiveness and other factors, breast cancer treatment usually involves removal 
surgery for the breast tumour and surrounding tissue or removal of the full breast and 
axillary lymph nodes (Aydiner et al., 2016). Chemotherapy before or after surgery, 
as well as radiation therapy after some surgeries is used to try to remove any residual 
cancer cells, in addition to hormonal therapy and targeted therapy (Aydiner et al., 
2016; Mainiero et al., 2016). When treating breast cancers, the body’s cells are 
targeted, as such, so most treatments will affect the malignant cells as well as normal 
cells. Even highly targeted treatments like narrow focus radiation may affect normal 
cells near the target cancer (Aydiner et al., 2016). It is the impact on normal cells 
which is the source of many treatment side effects, and from here the call for more 
specific targeted treatment arises. Each therapy’s side effects depend on its type, 
therapy period time and the patient’s own body (Aydiner et al., 2016; Mainiero et al., 
2016).  
Breast cancer tissue is under hormonal control (Hennighausen et al., 2001), 
regulated by the two main hormones estrogen and progesterone that maintain normal 
cell growth, proliferation and differentiation, in addition to milk duct growth and 
milk formation. Despite their important role in normal breast tissue, and other than 
age, estrogen is the greatest risk factor for developing breast cancer, followed by 
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progesterone. The more exposure an individual has to estrogen and the less they have 
to progesterone, the higher the risk of developing breast cancer. This relationship is 
the basis of hormone based therapy, which is among the first line treatments for 
breast cancer (Hammond et al., 2010). 
For its full and proper function, the estrogen hormone works alongside many 
Nuclear hormone receptor co-activators (NCoAs), that facilitate the transcriptional 
regulation of many genes by NHRs to activate gene expression, are one of many co-
enzymes in the NHR pathway to assist signal transmission in gene expression (Ren et 
al., 2013). The precise identity of NCoAs binding to an activated hormone receptor 
affects how a cell responds to hormonal stimulation, and the process of NCoA 
binding is itself mediated by interactions with other cofactors. Potentially functional 
single nucleotide polymorphisms (SNPs) in the coding sequence of an NCoA may 
alter the interaction of NCoA with its cofactors, and through this, NHR mediated 
gene expression (Ren et al., 2013). 
Proteins, involving receptors and co-activators have as important a role as 
estrogen in transmitting hormonal messages (Shang et al., 2000). Since estrogen 
stimulation through the estrogen nuclear hormone receptor is a major mechanism 
through which the effects of estrogen are mediated, then changes in the properties of 
nuclear hormone receptor (NHR) pathways can lead to altered hormone effects, 
making inherited genetic variants affecting NHR pathways able to alter estrogen’s 
effect on BC susceptibility (Shang et al., 2000). 
Very few SNPs in NCoAs have been researched in previous studies, leaving us 
with a very poor knowledge about their effect on estrogen hormone signalling and 
the development of breast cancer. This study was conducted to investigate the 
relationship between three SNPs in NCoAs and BC susceptibility. Gaining an 
understanding of how these SNPs interact with estrogenic effects on BC risk could 
lead to us developing more effective guidelines for BC screening and a basis for 
research into their effect on BC treatments based on anti-estrogen hormones. Thus 
my research may be a first step to understanding this impact on both treatment and 
susceptibility.  
In this study I have examined three NCoA SNPs, including rs1804645 in 
NCoA1 which acts as a transcriptional co-activator for steroid and NHRs (NCBI, 
accessed 2017), rs2230782 and rs2076546, both in NCoA3, which interacts with 
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NHRs to enhance their transcriptional activator function to determine their role in 
BC risk (NCBI, accessed 2017a). The location of the genes containing these 
polymorphisms can be seen in Figure1.1. These SNPs have the potential to 
significantly alter the risk of BC development, and two of them are potentially 
functional, altering the amino-acid sequence of the protein produced by the gene. 
Figure 1.1. Chromosome Localisation of the NCoA1 and NCoA3 Genes. NCoA1 is 
located on the short arm of Chromosome 2, at p23.3. NCoA1 acts as transcriptional co-
activator for steroid and NHRs. NCoA3 is located on the long arm of Chromosome 20 at 
q13.12. NCoA3 interacts with NHRs to enhance their transcriptional activator function. 
Adapted from: (Genecards, accessed 2015a, accessed 2015b). 
The main purpose of this study is to develop significant knowledge on how 
SNPs in NCoAs may affect breast cancer development to advance my understanding 
of this disease. The knowledge achieved has the potential to open many doors for 
more specific screening, early detection and targeting treatments, with the hope of 
obtaining full cures in more cases. The research also intends to highlight the 
importance of new knowledge of hormonal effects in breast cancer so future 
researchers will be able to open up new avenues to enhance my knowledge of the 
disease and reach a time where we can change the health and wellbeing of all those 
affected by breast cancer. 
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1.3 AIMS AND PURPOSE 
 
NCoAs play important roles in the nuclear hormone receptor pathway. Since 
NCoAs are important regulators, and play a major role in modulating the 
transcriptional activities of nuclear hormone receptors, any polymorphisms in them 
can have potentially wide-ranging effects on their target (Bhan et al., 2017). As a 
result, I are undertaking this research in order to better understand the effect of these 
polymorphisms on NHR pathways, and their effect on the risk of sporadic breast 
cancer. Characterisation of polymorphisms in NCoAs may help to increase my 
understanding of their contribution to cancer development and improve my ability to 
estimate breast cancer risk in individuals. This in turn may help improve the ability 
to screen for and detect breast cancers at an early stage and better my knowledge of 
breast cancer and earlier diagnosis toward the elusive goal of a cure for breast cancer 
(Penney, 2017). Predictive models for breast cancer risk have been established and 
tested for familial breast cancer, but more data is needed to understand the role of 
genetic variants in sporadic breast cancers (Fischer et al., 2013). 
The general aim of this study is to genotype individuals with and without 
sporadic breast cancer for three polymorphisms to obtain sufficient data to evaluate 
whether the results support my hypothesis. There are 2 main approaches and one aim 
for this study. 
The two approaches are: 
1. To amplify genomic DNA containing each of the three target SNPs in 
a cohort of breast cancer cases and matched controls. 
2. To genotype each of the target three SNPs in a cohort of breast cancer 
cases and matched controls. 
The aim of this study is: 
1. To identify the impact of the three targeted SNPs and their association, if any, 
with breast cancer. 
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1.4 PROPOSED HYPOTHESIS 
 
The candidate SNPs investigated in this study have been researched in familial, 
but not sporadic breast cancer, where two have been found to be breast cancer 
protective SNPs. On the basis of evidence from these previous studies, I hypothesise 
that these SNPs affect susceptibility to sporadic breast cancer. I hypothesise that as a 
result, the frequency of alleles and genotypes will differ significantly between the 
breast cancer cases and the control population. Consequently, the null hypothesis 
states that there will be no significant difference between the breast cancer cases and 
controls for allele and genotype frequencies of these SNPs.  
In addition, I have a secondary hypothesis. The effect of my target 
polymorphisms may be altered by exposure to lifestyle factors. My secondary 
hypothesis is that the relationship of allele or genotype frequencies to breast cancer 
risk may be altered if the population is analysed in the context of personal factors 
such as obesity, age at menopause, smoking, childbearing, and other factors that are 
risks for or protective against breast cancer. I hypothesise that this will result in 
differing allele or genotype frequencies in women with different breast cancer risk 
factors. The alternative hypothesis for this scenario is that there will be no difference 
in the ability of the target SNPs to predict breast cancer risk when these factors are 
taken into consideration. 
By examining these SNPs, I will gain a better understanding of their 
contribution to BC risk in individuals and better knowledge on how this disease is 
instigated and progressed. This in turn may help improve my ability to screen for and 
detect breast cancers at an early stage and better my knowledge of BC and earlier 
diagnosis toward the elusive goal of a cure for BC. 
 
1.5 CONCLUSION 
 
All types of cancers are extremely complicated diseases resulting from the 
various capabilities of a cancer cell such as maintaining rapid proliferation, limitless 
growth and the ability to make use of signalling molecules in its surrounding 
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microenvironment to strengthen its position (Tomasetti et al., 2017).  As such, there 
remains a huge knowledge gap when it comes to understanding the mechanisms of 
cancer. However, with the genetic revolution researchers are now in the first stages 
of unlocking this cancer knowledge gap. Studying the human genome provides the 
opportunity for more understanding of what is happening inside the human body in 
the presence of cancer (Hubner et al., 2017; Penney, 2017). Additionally, genomic 
work may help lead to a future of very early detection which, in the presence of other 
advanced diagnosis and treatment techniques can lead to an increase in cancer patient 
survival rate and perhaps to an ability to provide a full cure (Penney, 2017). 
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Chapter 2: Literature Review 
 
2.1 HISTORICAL BACKGROUND 
 
Looking back at the history of cell biology and tumours, there were several 
highlight years when many attributes of cancer were illuminated by research and my 
knowledge of the disease was radically changed. This improved understanding of 
cancer has played an important role in all the improvement in the diagnosis and 
treatment of cancer that we have achieved in the present day. In the late 1830’s, 
Johannes Muller described the morphological abnormalities in the nuclei and cell 
bodies of tumour cells (Bignold et al., 2006), which was itself only achieved after the 
massive progress in microscopic studies and discoveries from the beginning of 16th 
century to the early 18th century (Bignold et al., 2006). Identification of structural 
abnormalities was followed by the description of mitosis and chromosomal 
abnormalities in a cancer cell in the late 1880’s. 1890 was a remarkable year when 
Von Hansemann was the first to suggest the theory that cancer cells develop from 
normal cells where the chromosomes are at a risk of developing a mutation during 
mitosis (Bignold et al., 2006). Unfortunately, his theory was rejected due to the lack 
of knowledge of cell biology, insufficient technology and poor evidence available at 
the time. However after 70 more years of scientific research progress and 
development, this theory was recognised with the identification of single mutations 
in cancers (Bignold et al., 2006), a discovery that was then followed by the 
observation of the role of multiple mutations in cancer (Bignold et al., 2006). 
Cancer is a disease that has been affecting humanity for millennia. For 
example, in the 16th century, bone cancer was found in mummies from ancient Egypt 
(Sudhakar, 2009). Amongst the various kinds of cancer, breast cancer is perhaps the 
one with the longest recorded medical history, since the first written reference to 
cancer of any kind was a case of breast cancer documented in Egypt around the 15th 
century BCE (Sudhakar, 2009).  
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2.2 BREAST 
 
2.2.1 Breast Anatomy and Tissue  
 
The breast is a complex structure that is made up mostly from glandular tissue 
and fibrofatty stroma including lobes, lobules, ducts, lymph nodes, fat, connective 
tissue, nerves, and blood vessels. The breast originates from the ectoderm (skin 
precursor cells) and overlays the chest wall muscles (pectoral muscle). Both females 
and males have breasts which are mostly the same at the early stages of 
development; differences appear after the full maturation of the breast during puberty 
where women will have more breast tissue compared to men. The matured female 
breast extends from just below the collarbone (clavicle), to the armpit (axilla) and 
across to the breastbone (sternum) as shown in figure 2.1 (Burstein et al., 2008; Ellis, 
2010).   
 
 
Figure 2.1. Matured Female Breast General Anatomy. This schematic drawing shows 
the location of female breast and the surrounding structure. Adapted from: (CCS, accessed 
2017).  
 
The female matured breast is made up of many sections called lobules, which 
branch out from the nipple and are connected to it by thin tubes, ducts. Each lobule 
holds ten to 100 alveoli (a very tiny sac), which is the basic secretory unit, which are 
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surrounded by the fatty and connective tissue (Figure2.2) (Geddes, 2007). There is 
no muscle tissue in the breast; however the pectoral muscle, which lies under the 
breast, separates and protects the breast from the rib bones. Breast tissue gets oxygen 
and nutrient supplies through the blood vessels that are spread and embedded in the 
connective tissue. Breast blood supply varies depending on the physiological activity 
and function of the breast. The breast is also surrounded by a lymphatic network, 
found under the armpit and behind the breast bone, made up of lymph nodes and 
lymph ducts to maintain immune protection and help fight infection (Gudjonsson et 
al., 2005; Jesinger, 2014). 
 
 
 
Figure 2.2. Breast Internal Anatomy. This schematic drawing shows the anatomical 
structure of a matured female breast. Lobules formed by clusters of alveoli are connected to 
ducts, leading to the nipple. Lobules are surrounded by fatty and connective tissue, all lying 
atop the pectoralis major muscle and the ribs. Adapted from: (CCS, accessed 2017). 
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2.2.2 Breast Development and Maturation 
 
The breast undergoes many changes, which are dependent on genetic factors 
and hormone stimulation, as well as inputs from lifestyle, diet and support given 
during and after each development stage. All of these affect its structure, function, 
and size. The following are the development periods the breast goes through: 
• Gestation period (embryonic development): the first breast cell 
differentiation and early development will take place in this stage. 
Between the fourth/fifth to the twelfth weeks of gestation and under 
hormonal and genetic influences, the first epithelial mammary bud of 
the breast starts developing. The growth of more mammary buds is 
followed by the formation of secondary buds then the formation of 
mammary lobules. After the twelfth week of gestation the growth of the 
mammary lobules continues with their branching into 15-20 branches 
of cells differentiated into solid epithelial columns which are converted 
just before birth into lactiferous ducts leading to a complex network 
where all the ducts are connected to the developing nipple, which everts 
after birth (Davis, 2010; Jesinger, 2014).  
• Birth to pre-puberty period (Pre-puberty): the breast function and 
development is slowed down in this stage, or enters an equilibrium 
phase. The breast is made up of just lactiferous ducts in this phase and 
remains dormant. In this stage the breast structure and size is the same 
for both males and females where the amount of the fatty tissue present 
determines the size of breast (Davis, 2010; Jesinger, 2014). 
• Puberty period: the main breast development in this stage is the 
maturation of the fibro-glandular system in addition to lobule 
proliferation. With the onset of puberty the size of the breast varies 
between males and females where breast enlargement occurs far more 
commonly in the females (Davis, 2010; Jesinger, 2014). 
• During pregnancy and lactation period: in this stage, due to the high 
hormonal level secretion, the development and differentiation of the 
secretory alveoli and the maturation of the fibro-glandular system 
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occurs. This results in the culmination of breast function which is milk 
production. During breast feeding, the produced milk is carried by the 
ducts from the alveoli to the areola, and then all the branched ducts are 
joined together into large ducts carrying the milk to the nipple. Blood 
supply increases in the breast during this stage (Davis, 2010; Jesinger, 
2014). 
• Post-menopause period: the major transformation of the breast in this 
stage is the disappearance of most of the glandular lobules and 
predominance of fat. After menopause, the fat component increases 
within the breast, replacing the shrinkage and loss of fibro-glandular 
tissue and surrounding connective tissue volume. The formation of 
lobules may continue as microcysts which will appear in breast imaging 
and may be confused with disease cysts (Davis, 2010; Jesinger, 2014). 
 
The breast also contains lymph nodes, which are an important factor in breast 
morphology as far as cancer is concerned. The breast lymph nodes and lymph vessels 
are part of our body's lymph network which serves as part of the immune system, 
facilitating the development of immune cells and specific immunity. The breast 
lymph nodes include the supraclavicular nodes, infraclavicular nodes, axillary nodes, 
and internal mammary nodes (figure 2.3) (Geddes, 2007). 
 
Figure 2.3. Breast Lymph Nodes. This schematic drawing shows the location of the 
different types of lymph nodes. Adapted from: (CCS, accessed 2017). 
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2.2.3 Breast Function 
 
The main function of a matured female breast tissue is the production, 
secretion and the storage of milk enabling nutrition of newborns and babies. Since 
the breast is a hormonally dependent organ, the production of the milk in the lobules 
is stimulated by hormonal secretion, and then carried through the ducts to the nipple 
and then passes to the baby during breast feeding (Marieb, 2012). Estrogen and 
progesterone are the main hormones affecting and stimulating growth in normal 
breast cells. Each month, women experience a normal menstrual cycle due to 
fluctuations in hormone levels. Estrogen, produced in the first half of the menstrual 
cycle by the ovaries, is the primary growth inducing hormone in the breast, 
stimulating the growth of milk ducts. Progesterone, produced in the second half of 
the menstrual cycle, is the 2nd major hormone in the breast and controls cellular 
differentiation, by stimulating differentiation and formation of the milk glands 
(Kelsey et al., 1993). For milk production, two essential hormones are needed: 
prolactin and oxytocin. Prolactin hormone stimulates milk production by binding to 
the mammary epithelial cell receptor, leading to the synthesis of mRNAs for milk 
protein (Akers, 2016). Oxytocin hormone stimulates the ejection of milk so the milk 
can be removed from the breast (Akers, 2016). Breast tissue function (milk 
production) in stimulated during the pregnancy stage after the cyclical phases that the 
breast tissue experiences during normal menstruation. During pregnancy, high levels 
of estrogen hormone are secreted to induce the proliferation of the ductal system, the 
maturation of the nipple and the fat deposits in the breast (Figure 2.4). On the other 
hand, the progesterone hormone, released in increasing amounts during a pregnancy 
influences the breast to increase the number of lobules and induces the secretory 
characteristics of the alveolar buds and alveolar cells. The prolactin hormone, which 
is secreted by pituitary gland, increases around ten times during pregnancy, and is 
important in initiating and maintaining lactation. 
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Figure 2.4. Breast Anatomy in Lactating and Non-lactating States. This schematic 
drawing of a longitudinal section of the breast compares the development and transformation 
that happens to the adipose tissue, lobules and ductal system between an inactive breast and 
lactating breast (during pregnancy). In addition to the gross morphology, a longitudinal 
section of an active mammary alveoli producing milk is shown, illustrating the cellular 
morphology. Adapted from: (Gartner et al., 2007) 
 
2.3 BREAST CANCER 
 
The breast like any other organ is subject to many different diseases. Some are 
non-tumour diseases like developmental disorders, functional disorders, regressive 
changes, or inflammatory changes. Some are tumour based breast diseases (Aydiner 
et al., 2016). Some of these are benign tumours, which may or may not be related to, 
or a precursor of, cancer, which forms malignant tumours, resulting in the clinical 
manifestation of breast cancer (Aydiner et al., 2016). Breast cancer is the main focus 
of this research study. 
 
2.3.1 Breast Cancer Statistics  
 
Breast cancer is a worldwide disease, affecting people socially, due to its high 
morbidity and mortality, as well as economically. Indeed, the estimates of lifetime 
patients cost of breast cancer in the US were $16.5 billion in 2010, and estimated to 
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raise up to $20.5 billion in 2020 (Mariotto et al., 2011). Breast cancer is more likely 
to affect women, who have a 100 times higher risk of getting this disease than men 
during their lifetime (Francescatti et al., 2013). Breast cancer was the third 
commonly diagnosed cancer in Australia after prostate (in males only) and bowel 
cancer (in both men and women) in 2011 and remains the third in 2015. Breast 
cancer has the highest incidence of any kind of cancer amongst women in Australia, 
with a 7.3 % increase of new cases, where the new breast cancer cases in 2011 were 
14,568 (103 males and 14,465 females), the estimated new cases in 2015 were 
15,740 (145 males and 15,600 females), and there are projected to be 17,586 new 
cases in women in 2017 (AIHW, 2015, 2017). In the United States, the estimated 
invasive breast cancer cases diagnosed will be 252,710 women and the death 
estimated to be 40,610 (Siegel et al., 2017). The age standardised incidence rate in 
Australia in 2011 was 60 cases per 100,000 persons (0.9 for males and 116 for 
females) while in 2015 the estimated rate was 59 cases per 100,000 (1.1 for males 
and 115 for females).  Though breast cancer is not the most common female cancer 
in all countries, it is the most common in the developed and most of the developing 
world (Figure 2.5). The estimated risk of an individual being diagnosed with breast 
cancer in 2015 after the age of 85 was one in eight in females (AIHW, 2015), while 
in 2017 it is estimated that one in eight would be at risk of breast cancer diagnosis 
before the age of 85 (AIHW, 2017). In Australia, the deaths due to breast cancer in 
females have risen by 8% from 2,819 (24 males and 2,795 females) in 2011 to an 
estimated 3,065 (25 males and 3,040 females) in 2015. The chance of survival in 
Australian women in the last five years was estimated to be 90% (AIHW, 2017). In 
US, the 2nd most common cause of death as a result of any cancer in women is breast 
cancer (14%) (Siegel et al., 2013). The female median age at death for breast cancer 
sufferers was 69.7 years, lower than the median age of all female deaths (84.5 years) 
by 14.8 (ABS, 2011). These statistics show that breast cancer is a significant health 
issue in the developed world and despite improvements to screening technologies, 
screening programs, and treatment in recent years (Lee et al., 2014); it is still a major 
killer. Since early detection of breast cancer significantly improves patient survival 
(Thomson et al., 2004), a better understanding of the mechanisms of breast cancer 
may allow us to further reduce the impact of the disease. 
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Figure 2.5. Female Most Common Cancer by Site Worldwide and Incidence.a) Breast 
cancer (pink) is the most common cancer by site amongst women in most countries 
worldwide, except some countries where other sites are more common, such as lung, 
bronchus & trachea cancer (light blue) in China, cervical cancer (red) in Peru, Papua New 
Guinea, Nepal, south and east Africa, etc. and liver cancer (light green) in Mongolia. b) 
Breast cancer incidence per 100,000 people is highest primarily in the developed world. 
Adapted from:(ACS, accessed 2015). 
a 
b 
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2.3.2 Breast Cancer Literature Review  
 
Breast cancer is a cellular disease, where cancer is the end result of series of 
genetic changes. There are two main kinds of breast cancer, termed familial or 
sporadic, depending on whether the mutation causing cancer was inherited from an 
individual’s ancestor or whether the mutation occurred at random within a single cell 
(Harmer, 2011). Two main genes known to be mutated in familial breast cancer are 
BRCA1 and BRCA2 (Harmer, 2011). These two genes are only involved in a small 
proportion of breast cancers, and their disruption is associated mainly with familial 
breast cancer (Zheng et al., 2000). However, most breast cancer arises from the 
interaction of lifestyle factors and other genetic variation. These cancers are known 
as sporadic cancers, and they comprise ~90% of all breast cancer, making them the 
most relevant for public health and research (Zhang et al., 2003). One of the primary 
risk factors for sporadic breast cancer development is exposure to estrogen, and this 
can be modulated by the effect of other hormones, which are primarily mediated 
through the hormone gene receptors. 
 
2.3.2.1 Breast Cancer Types 
 
Breast cancer typing is based on 2 main classifications, histopathological and 
molecular. The histopathological classification of breast cancer is based on the 
region or cell type of the breast where the tumour originates from (Russo, 2016). 
Breast cancers are divided into 2 main histopathological types: invasive ductal 
carcinoma (~80% of all breast cancers) and; invasive lobular carcinoma (~20% of all 
breast cancers). In addition to these two major divisions, there are many other 
carcinoma subtypes including inflammatory carcinoma, apocrine carcinoma, 
medullary carcinoma, metaplastic carcinoma, micropapillary carcinoma, tubular, 
adenoid cystic carcinoma, mucinous carcinoma, neuroendocrine carcinoma and 
mammary Paget disease (Russo, 2016; Weigelt et al., 2009).These subtypes are 
defined by particular phenotypes displayed by the cancers, reflecting their biological 
properties. The molecular classification of breast cancer is based on differences in 
gene expression, which is determined using molecular techniques like DNA 
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microarray technology, immuno-histochemistry, fluorescent in situ hybridization, 
and quantitative reverse transcription polymerase chain reaction (Rouzier et al., 
2005; Russo, 2016). These techniques divide this classification into 3 main types, 
estrogen receptor / progesterone receptor positive tumours, estrogen receptor / human 
epidermal growth factor 2 negative tumours and triple negative (estrogen receptor / 
progesterone receptor / human epidermal growth factor 2 negative tumours). There 
are also subtypes of molecular classification, which are based on their basal or 
luminal cell type gene expression characteristics and these subtypes are divided into: 
human epidermal growth factor 2 type; basal like tumour; normal like tumour; 
laminal A tumour and laminal B tumour (Rouzier et al., 2005; Russo, 2016; Weigelt 
et al., 2009). These differences also reflect the biological properties of the cancers 
and can be used to guide patient management, especially as regards hormonal based 
therapies. 
 
2.3.2.2 Molecular Markers in Breast Cancer 
 
The detection of any breast cancer types or subtypes in order to provide the 
appropriate effective treatment requires a combination of accurate methods of 
detection; one of these methods is the presence of molecular markers (Ludwig et al., 
2005). Molecular markers, can be in the form of hormone receptors (estrogen 
receptor and progesterone receptor), growth factors (VEGF), antigen (Ki67), tumour 
protein (p53), breast cancer gene (BRCA1 and BRCA2), enzymes (TOPO II), 
nuclear antigen (PCNA) and many others. When measured and detected in the blood, 
other fluids or tissues their presence and often levels indicate the presence of normal 
process, pathogenic process or disease (Glynn et al., 2010; Gudlaugsson et al., 2012; 
Ventura et al., 2008; Zhao et al., 2012). Molecular biomarkers can also be used to 
follow up a disease treatment by showing how the body is responding (Mishra et al., 
2010). 
The classifications of molecular markers in breast cancer depends on the 
type/subtype of breast cancer and on the stage of the disease. The expression 
frequency or the presence of a marker varies between the type/subtype of the breast 
cancer (Park et al., 2010). These markers can be based on the disease state 
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(prediction, detection, diagnosis and progression markers), or based on biomolecules 
(DNA, RNA, protein markers) or based on other criteria (imaging and pathological 
markers) (Ludwig et al., 2005). More studies are focussed on molecular markers due 
their importance in the detection, diagnosis, progression and therapeutic purposes in 
breast cancer (Park et al., 2010). 
 
2.3.2.3 Genetic and cellular heterogeneity of Breast Cancer Types 
 
Breast cancer is a heterogeneous disease due the variation in its pathological 
features, its various responses to therapy and differences in patient survival (Polyak, 
2007). Breast cancer heterogeneity is reflected clearly in the breast cancer 
classification systems, including the cellular (histopathological) and the molecular 
classification of the disease. Histological classification is based on the tissue type 
where the cancer originates, with most cases categorised as invasive ductal 
carcinoma, along with physical characteristics of the tumour, like size and level of 
differentiation. By contrast, molecular classification is based on the behaviour of 
genes and proteins that are involved in the breast cancer with the molecular markers 
the main factors in diagnosis, progression and reaction of the cancer to treatment. In 
some cases there is a mixture of both classification systems within the same tumour, 
as different sub-lineages of the original cancer acquire new characteristics (Sambi et 
al., 2017). Due to this heterogeneity of breast cancer, previous studies have claimed 
that breast cancer is not a single disease but an array of related conditions with 
differing aetiologies and outcomes. This heterogeneity leaves the genesis and 
progression of breast cancer difficult to predict on an individual level. 
 
2.3.3 Breast Cancer Risk Factors 
 
There are many factors that affect the risk of developing breast cancer by either 
showing a protective or an increasing effect. Amongst those factors are the 
following: 
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Personal characteristics: gender is one of the main risk factors of BC, where 
women are at a higher risk of developing BC compared to men. Age is a strong risk 
factor where normally BC risk increases with age. BC can occur at a young age but 
most the cases are 50 years old and up. An increased BMI means an increase of fat 
cells, which leads to increase the estrogen hormone levels in the body (due to 
hormone production in adipose tissue), where exposure to estrogen is one of the main 
risk factors of BC (Colditz et al., 2004; Mcpherson et al., 2000). 
Body hormones: age of menarche, where reaching puberty at an early age 
increases the body’s exposure to estrogen hormone and other female hormones 
(through menstrual cycles) increases the risk of BC. Menopausal status, where 
women with late menopause have a higher risk of BC than women who hit 
menopause at the average age (~45 years old). An increased number of pregnancies 
leads to a decreased risk of developing BC, simply because the pregnancy will 
decrease the exposure to hormones that encourage growth of breast tissue and 
exposure to hormones prompting tissue differentiation. Being on hormone 
replacement therapy (HRT) also increases the risk of developing BC. Breast feeding 
for a longer time can lead reduced risk of BC (Mcpherson et al., 2000). 
Life style: geographical variation may affect risk where the BC risk is different 
between countries due to the different lifestyles of each country. Alcohol 
consumption as well as smoking are associated with an increased risk of BC. Diet 
and exercise also affect the risk of developing BC, where healthy active women are 
at a lower risk of BC than inactive women (Bernstein, 2002; Mcpherson et al., 2000). 
Family history and other factors: family history of BC and ovarian cancer can 
indicate an increased risk of developing BC. Radiation exposure may cause the 
development of mutations, increasing the risk of BC. Previous breast conditions with 
different cancer types also increase the risk of developing BC. Finally, genetic 
variation with the combination of the risks mentioned previously is a strong risk 
factor of developing BC (Colditz et al., 2004; Mcpherson et al., 2000). 
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2.4 HORMONES AND BREAST CANCER 
 
2.4.1 Estrogen and Progesterone 
 
Estrogen and progesterone hormones, which are mainly known as sex 
hormones, are secreted by the ovaries to maintain healthy female sex characteristic 
development during puberty and maintenance of adult fertility by being secreted on 
high or low doses depending on the menstrual cycle phase (Maki et al., 2002). In 
addition, both hormones target and affect many organs in the body. Estrogen and 
progesterone are the 2 main hormones affecting the normal function and maturation 
o breast tissue and during pregnancy (Hennighausen et al., 2001). Estrogen also has a 
direct effect on some brain areas such as the hippocampus that are specialised in 
controlling cognition (Spencer et al., 2008) and affects some central nervous system 
function (Mcewen et al., 1999). 
Despite the importance of estrogen and progesterone for normal mammary 
gland development, it is increasingly recognised that they are strongly associated 
with breast cancer incidence, where estrogen induces cellular proliferation in most 
breast cancers and progesterone has an antagonising effect. Previous studies have 
reported that individuals with a longer exposure to estrogen have an increased risk of 
developing breast cancer (Russo et al., 2006). Thus, estrogen and progesterone 
receptors have been used as molecular markers to detect the presence and the 
severity of breast cancers (Harris et al., 2016).  
Breast cancer treatment has been developed in the last 2 decades to be more 
targeted and specific; however it is still dependent on the type, stage and the 
aggressiveness of the tumour (Zurrida et al., 2015). Many forms of treatments have 
been introduced over the years including breast surgery, radiotherapies, 
chemotherapies, hormonal therapies and various targeted therapies (Aydiner et al., 
2016; Cole et al., 1971; Devita et al., 2008; Passant et al., 2013). Each therapy is 
dependent on the patient’s particular characteristics, breast cancer stage, whether the 
cancer is hormonally sensitive or not, the size and aggressiveness of the tumour and 
the situation of the patient and whether they can undertake a particular treatment 
(Zurrida et al., 2015). Breast surgery is mainly used for early breast cancer tumours 
 
 
Chapter 2: Literature Review 31 
 
and can involve mastectomy or breast conserving surgery, in addition to removal of 
lymph nodes from the armpit (Aydiner et al., 2016). Radiotherapy is recommended 
usually after a breast surgery (Aydiner et al., 2016). For early breast cancer stages 
with a risk that the tumour cells may have spread outside the breast area or the armpit 
area then chemotherapy is recommended (Devita et al., 2008). Hormonal therapy is 
manly used for hormone sensitive tumours and works by blocking the hormonal 
effect on cancer cells or altering the body’s hormonal production. It includes 
adjuvant therapy for early stage breast cancer such as Tamoxifen, and the treatment 
of advanced breast cancer using neoadjuvant therapies (Chia et al., 2010). Along 
with the benefit of breast cancer treatments, however, their side effects are still 
strong, leading to many physical and even mental health problems. 
 
2.4.2 Nuclear Hormone Receptors 
 
During the era of intermediary metabolism and enzymology, in the late 1950s, 
Elwood Jensen was credited with the discovery of the first member of the nuclear 
hormone receptor (NHR) family, known as the estrogen receptor (Khan et al., 2010; 
O'malley et al., 2013). The nuclear receptor gene family is a large family of genes, 
whose members function as sequence specific transcription factors, controlling target 
gene transcription by binding as homodimers to a response element on target genes 
(Khan et al., 2010). The steroid nuclear receptors, a sub-family of the nuclear 
hormone receptors, are specific receptors for steroid hormones (Keightley, 1998) 
functioning to control growth and differentiation in many tissues (Dickson et al., 
1990).  
NHRs signal from their specific ligands, for example the estrogen hormone, 
and alter gene expression or affect cell behaviour directly. Many of the functions of 
the hormones in the cell are thus mediated by the NHRs (Francis et al., 2003; 
Mangelsdorf et al., 1995). Most importantly for breast cancer, they affect the cellular 
growth and differentiation of breast tissue (Kelsey et al., 1993). As a result, changes 
in the functions of the NHRs have the potential to influence the development, 
diagnosis and clinical management of breast cancer, underscoring their importance in 
breast cancer research.  
 
 
Chapter 2: Literature Review 32 
 
 
2.4.3 Nuclear Hormone Receptor Co-activator 
 
Within the NHR pathway (Figure 2.6), many co-enzymes are included that 
assist, promote, and regulate NHR signal transmission and changes in gene 
expression in target loci (Xu et al., 1999). Amongst these co-enzymes are the nuclear 
hormone receptor co-activators (NCoAs). The best characterised of these are 
NCoA1, NCoA2 and NCoA3, all members of p160 SRC gene family (Xu et al., 
2009). These NCoAs are strong boosters of gene expression, where they facilitate 
transcriptional protein complexes and activate gene expression by allowing the 
NHRs to bind to one another, a critical part of their ability to bind to hormone 
response elements in genes (Li et al., 2006; Xu et al., 2009). Additionally, it has been 
determined that different NCoA transcripts produced from the same gene can have 
markedly different activation activity for estrogen (Xu et al., 2009). Recent studies 
also showed that NCoAs have a dual role of activation and proteolysis of estrogen 
hormone (Zhou et al., 2014). Thus, any factor that affects the function or expression 
of NCoAs, may have a huge impact on the risk of developing BC. Despite this, 
research in our laboratory has indicated that of the three best known NCoAs, only 
NCoA1 and NCoA3 show significant change in expression during breast cancer 
progression (Smith et al., 2010). As a result, these genes were the primary focus of 
this study. 
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Figure 2.6. Nuclear Receptor Hormone Pathway. This figure shows the mechanism of 
nuclear hormone receptor action. Hormone ligand binds to the NHR, and an NHR dimer is 
formed. Then translocation into the nucleus takes place. There, with the help of many co-
enzymes that can act in activating and repressing manners, the NHR dimer binds to target 
genes containing a hormone response element, which affects transcription of the gene, 
resulting in a change in cell function. Adapted from: (Ren et al., 2013). 
 
2.5 BREAST CANCER AND GENETICS 
 
Almost every cell of the human body or any living organism carries DNA, 
which contains all the information that represents the profile of that particular 
organism (Hood et al., 2003). DNA is a highly robust molecule due its double 
stranded helix shaped molecular structure and the multiple hydrogen bonds between 
its two strands (Garwin et al., 2010; Hood et al., 2003), requiring relatively high 
temperatures to break down (Altan-Bonnet et al., 2003). Human DNA can be 
extracted from various types of tissues and can be stored for long periods for 
analysis, diagnosis and research purposes. Human DNA is exposed to many genetic 
variations and alterations (Ellisen et al., 2010; Koren et al., 2014). The accumulation 
of these alterations and variations could lead to an abnormal and uncontrolled cell 
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proliferation, followed by invasion to the surrounding tissues and metastasis to other 
far sites, resulting in the formation of cancer and tumour progression (Koren et al., 
2014). 
 
Cancer can be a result of an inherited genetic mutation, such as mutations in 
the BRCA1/BRCA2 genes (leading to breast and other cancers) (Antoniou et al., 
2010), or many environmental factors interacting with the individual’s overall 
genetic variation, such as long term exposure to ultraviolet radiation (leading to skin 
cancer), cigarettes (leading mainly to lung cancer), age (due to accumulation of 
random somatic mutations) with the combination of other factors which for breast 
cancer include hormones, body mass index (BMI), pregnancy, breast feeding or other 
elements that may encourage cellular growth and increase the likelihood of a 
mutation occurring (Antoniou et al., 2010; Desantis et al., 2014). 
Depending on the type of genetic variation involved in its generation defines 
the basic type of breast cancer (Mavaddat et al., 2010). Familial breast cancer arises 
from an inherited gene variant, while sporadic breast cancer is due to the 
accumulation of somatic mutations interacting with environmental factors (Partipilo 
et al., 2016). Familial breast cancer can be predicted since it passes through a family 
with the genetic variant so family members are aware of the probability of 
developing the disease. In contrast, sporadic breast cancer occurs due to the exposure 
of the individual to breast cancer environmental risk factors and is therefore harder to 
predict. Inherited cancer causing variants are rare, however, and most breast cancer 
cases that arise are the sporadic type (Mavaddat et al., 2010; Partipilo et al., 2016). 
With the current era of genetic revolution, almost any disease can be 
investigated to identify its mechanisms and what it does in human body; simply by 
studying the genome and the variances that it undergoes as a result of the disease 
(Henderson et al., 2008; Montgomery et al., 2014; Risch et al., 1996). Since the 
development of sporadic breast cancer is based in part on gene variation, the 
development of multiple new gene analyses methods is enabling great strides to be 
made to increase our knowledge of sporadic breast cancer and many other diseases 
(Ritchie et al., 2001). This process is a long term journey since human DNA is a 
complex molecule, but new advances made by research and the combination of 
results of the studies performed is enabling us to move toward a time in the future 
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where we can understand with great precision how cancer and similar diseases work. 
This may enable the deployment of techniques for earlier diagnosis and risk 
management, which will result in higher success rates of available treatments and 
higher survival rates. 
This research is complementary to previous work undertaken by our lab that 
has examined the effect of single nucleotide polymorphisms (SNPs), which are any 
single base change in the human genome that leads to change the function of a gene 
by stimulation of altered function, or inhibition (Figure 2.7) (Zhao et al., 2013). Our 
studies have examined numerous SNPs for their association with the risk of 
developing breast cancer. Most of these studies were focused on SNPs found in 
hormone production enzymes (like the estradiol producing aromatases), NHR (like 
the estrogen receptor) or microRNAs directly affecting these genes.   
 
 
Figure 2.7. Single Nucleotide Polymorphism. This schematic drawing shows a single 
nucleotide polymorphism (SNP) in a DNA sequence. The normal DNA sequence was a C 
with G complimentary base, where the SNP occurs the C changes to a T allele with a 
complementary A nucleotide. Adapted from: (IBBL, accessed 2015). 
The latest genome wide association study (GWAS) outcomes in relation to 
identifying SNPs with breast cancer risk, have examined a  significant array of SNPs, 
including a SNP located on chromosome 2 (where the NCoA1 gene is located) 
(Nagrani et al., 2017). One of the four identifies ER negative-specific breast cancer 
risk loci, rs12710696 located on chromosome 2 at position p24.1 which is relatively 
close to my candidate SNP NCoA1 rs1804645 located at position p23.3 (Garcia-
Closas et al., 2013). None of my proposed SNPs were identified directly in any of 
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the GWAS studies, however the finding of paper Garcia-Closas implicated 
neighbouring SNPs that are associated with breast cancer risk does raise the 
possibility that study into NCoA1 at least may yield some interesting results in terms 
of any association with breast cancer. 
Some of our lab studies, as well as those of others, have shown negative results 
for the association of SNPs with breast cancer, so not all polymorphisms are 
effective in altering breast cancer risk (Gabrovska et al., 2011; Jedlinski et al., 2011; 
Kang et al., 2014; Ramadan et al., 2014). At the same time, some of our lab studies, 
as well as those of others, have shown significant association of polymorphisms with 
breast cancer risk (Gabrovska et al., 2011; Hsieh et al., 2009; Ramadan et al., 2014; 
Smith et al., 2012). The effect of a SNP on breast cancer risk is a related to the 
degree of any functional effects on the metabolic pathways it involves, and whether 
those changes intersect with elements of the metabolic pathway that affect cancer 
initiation.  
The presence of SNPs in the coding sequence of the NCoAs potentially alters 
the ability of the hormone receptor resulting in expression changes and altered NHR 
function, through changes to primary protein structure and related effects. Any 
alteration in sensitivity to hormones would influence the risk of developing breast 
cancer. It is this potential that makes the Nuclear Receptor Co-activators the genes of 
interest for this research. 
 
2.6 CANDIDATE SNPS OF THIS STUDY 
 
Candidate SNPs have been selected through examination of sequence maps 
available at the NCBI website, examining the length of the NCoA genes for 
potentially functional SNPs and determining their known relationship to breast 
cancer, if any. Three candidate polymorphisms (Table 2.1) were identified and 
primers designed using Primer3 for polymerase chain reaction for genotyping 
analysis as detailed in the Methods section. 
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Table 2.1. Candidate SNP Characteristic. This table represents information 
about single nucleotide polymorphisms (SNPs), their referece number in the SNP 
database at the National Centre for Biotechnology Information (NCBI) in the United 
States, their location within the co-activator proteins, their type and other relevant 
facts for this study’s proposed SNPs. Abbresviations used include: MAF (minor 
allele frequency) and CEU (code for the Utah Residents with Northern and Western 
European Ancestry population used in population studies at the NCBI). 
Number SNP Name Location Type Facts 
1 
rs1804645 
(NCBI, 
accessed 
2017b)  
NCoA1 
Non-
synonymous 
SNP 
(Pro1272Ser) 
Has been 
demonstrated to 
affect  protein 
function  
MAF in HapMap 
CEU population = 
0.04 
2 
rs2230782 
(NCBI, 
accessed  
2017) 
NCoA3 
Non-
synonymous 
SNP 
(Gln586His)
MAF in HapMap 
CEU population = 
0.13 
3 
rs2076546 
(NCBI, 
accessed 
2017c)  
NCoA3 
Synonymous 
polymorphism 
(Thr960Thr) 
MAF in HapMap 
CEU population = 
0.11 
 
 
After identification, each of these three SNPs was chosen based on research 
history: 
First SNP: rs1804645 has been investigated in familial breast cancer 
populations, where it showed no association with familial cancer risk (Hartmaier et 
al., 2009); however it has not been studied previously in sporadic breast cancer. It 
has also been shown to alter response to tamoxifen (an estrogen antagonist used in 
treating breast cancer) in bone tissue (Bauer et al., 2007; Hartmaier et al., 2012). 
Thus, despite its lack of association with familial breast cancer, its potentially 
functional effects seem potentially important to breast cancer biology. 
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Second SNP: rs2230782 has been seen to be protective in German, Polish and 
US populations of familial breast cancer patients (Burwinkel et al., 2005; Hartmaier 
et al., 2009), but it has not yet been interrogated in sporadic breast cancer. It thus 
may have a similar effect in sporadic cancer and was deemed worthy of research. 
Third SNP: rs2076546 has been shown to be protective in a German and a 
Polish breast cancer population (Burwinkel et al., 2005), however this was not 
significant in a US population tested later (Hartmaier et al., 2009). Both these studies 
were in familial breast cancer, but like the other SNPs under investigation, the SNP 
has not been looked at in sporadic cases. I am thus conducting the first study on the 
SNP in a sporadic breast cancer context to determine if the protective effect seen in 
the European familial BC populations can be replicated. 
According to the HapMap data available on NCBI, the proposed SNPs in this 
study have the following frequencies: 
 
Table 2.2. HapMap Data of Candidate SNP.  This table includes frequency 
data for the candidate SNPs in this research, based on the European populations 
obtained from the HapMap project. 
SNP 
Individual 
Group 
Chromosome 
Sample Count 
Wild type 
Homozygote 
Heterozygote 
Mutant 
Homozygote 
rs1804645 
(NCBI, 
accessed 
2017b) 
European 226 
C/C 
0.929 
C/T 
0.071 
T/T 
0 
rs2230782 
(NCBI, 
accessed  
2017) 
European 120 
G/G 
0.750 
C/G 
0.233 
C/C 
0.017 
rs2076546 
(NCBI, 
accessed 
2017c) 
European 226 
T/T 
0.814 
C/T 
0.159 
C/C 
0.027 
 
Whether these polymorphisms alter risk in sporadic disease is an important 
consideration for their ability to predict risk in the general population, and may be 
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independent of results in familial cancers, due to interactions with specific familial 
genetic factors. 
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Chapter 3: Research Design 
3.1 OVERVIEW  
 
This research was a case-control association study. I used a population of 
sporadic breast cancer patients and age and sex matched control samples to evaluate 
the association of SNPs in NCoAs with breast cancer. I identified and examined three 
SNPs in these genes, using High Resolution Melting (HRM) where possible, with 
Restriction Fragment Length Polymorphism (RFLP) as a backup where HRM could 
not be used. I determined the genotype frequencies for chosen polymorphisms in the 
two cohorts (cases and controls) and evaluated associations with breast cancer risk. 
Chi-square analysis was used to determine the significance of any associations; 
population integrity was checked through conformance to the Hardy-Weinberg 
Equilibrium (HWE) and any association to breast cancer followed by determination 
of specific risks for cancer development using Odds Ratios. 
 
3.2 STUDY POPULATION  
 
The population used for this study consisted of 486 participants, 276 women 
with breast cancer (cases) and 210 healthy women (controls). The samples were 
matched for age (within five years), sex, and ethnicity (Caucasian). This matching 
served to reduce the effects of major risk factors for breast cancer (age and gender) 
and enable more accurate determination of genetic effects. Breast cancer cases and 
control samples also had no known family history of breast cancer in order to 
eliminate any effect of familial mutations on the results of the study. All cases were 
women with an average age of 57 years (56 years for controls) with a histologically 
confirmed diagnosis of invasive breast cancer. More specific information regarding 
staging and histopathological or molecular subtype was not available, restricting the 
study to being able to assess genetic effects on general breast cancer susceptibility 
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only. These samples were recruited in collaboration with the Gold Coast Hospital, 
and consisted of women from Queensland, Australia. Consent was obtained from all 
participants and ethics approval had already been obtained for this study (QUT 
Approval number: 1400000104). Information regarding risk factors for breast cancer 
(BMI, number of children, age at menarche, age at menopause) was also available 
for some samples for analysis. 
Most the DNA samples of this population were previously extracted from 
blood using a modified salting out method, cleaned and diluted to the working 
concentration needed by colleagues in the Genomics Research Centre (GRC) lab and 
stored in water. Since this project continues from previous research done in the GRC, 
these ready DNA samples were used. Some DNA samples in the working trays had 
been exhausted, so their original DNA stock was located and they were quantitated 
(using the NanoDrop method) in order to see if they needed any purification (Ethanol 
precipitation method) prior to dilution to an appropriate DNA working concentration. 
 
3.3 METHODS 
The following methods were conducted to fulfil the aims of this study: 
 
3.3.1 NanoDrop Spectrophotometry 
 
Spectrophotometry is a quantitative method that is used to measure the 
concentration of many samples like DNA, RNA, and Protein by measuring the UV 
absorbance then determining the concentration of the sample (quantitative results) 
and determining the purity of the sample (presence of any contamination) (Figure 
3.1). Spectrophotometry in this project was undertaken using a NanoDrop 8000 
Spectrophotometer (Thermo Scientific, Seventeen Mile Rocks, Australia) and was 
used to measure the DNA concentration in each sample of the population and its 
purity. Since the DNA population samples were extracted using a salting out method 
then the presence of residual salt may have interfered with the purity of the sample as 
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an element of contamination. Proteins that remained bound to the DNA even after 
extraction were another potential source of contamination that may have affected 
downstream analysis.  
The quantitative results produced by the NanoDrop were presented in tables 
and curves. The tables presented the concentration of the DNA in ng/µl, in addition 
to the values of absorbance ratios that help in reading the purity of the sample. 
Samples used in this research were checked to ensure their concentration and purity 
prior to PCR. Example data from the population used in this research are presented in 
Table 3.1 and Figure 3.1, below. 
 
Table 3.1. Example NanoDrop Nucleic Acid Quantitative Results.
 
This table shows the concentration of the DNA in four duplicated samples in addition to 
some ratios 260/280 and 260/230. Each sample was duplicated to lower the percentage of 
error and get more accurate results. In all four samples the results of the same sample 
duplicate tubes were similar with only slight differences. In sample 1 and 2, DNA 
concentration was low, while 260/280 ratio was higher in sample 1 and lower in sample 2 
than the normal threshold (1.8) indicating presence of contamination. Those sample needed 
additional purification. Sample 2 showed a good DNA concentration but very low 260/280 
ratio indicating possibility of contamination and requiring purification as the next step before 
making use of it. Sample 3 is an example of a good pure DNA sample, where the 260/280 
ratio is around 1.8 in addition to the presence of a good amount of DNA in the sample. This 
sample undergoes dilution to reach the proper working concentration. 
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Figure 3.1. NanoDrop Nucleic Acid UV Absorbance Results. This figure shows the UV 
absorbance results of the same four duplicated DNA samples presented in Table 3.1 stored in 
water buffer obtained from the NanoDrop instrument (Thermo Fisher). Curves labelled “1” 
show a sharp decrease without a peak at 230 nm indicating a relatively high salt level 
compared to the DNA peak. At 260nm the curve was steady without any peaks indicating a 
low concentration of DNA. There is a slight peak at 280nm indicating the presence of a 
small amount of protein contamination. For this sample an Ethanol precipitation should take 
place but care should be taken due to the low amount of DNA present in the sample which 
may be lost through precipitation procedures. The curve s labelled “2” show a similar 
pattern, but with a higher concentration of DNA and contaminants. Precipitation can be 
performed here with little concern. Curves labelled “3” show a typical pure spectrum pattern 
for nucleic acid (DNA), where I can notice only one peak at the 260nm indicating the UV 
absorbance of the DNA with no other peaks, indicating the purity. Curves labelled “4” are 
bad samples with no trace of DNA in them and required re-extraction.  
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3.3.2 Dilution  
 
In this study, dilution was used to get a consistent concentration of DNA and 
experimental reagents according to each protocol used. The working DNA 
concentration used in this study was 20ng/µl. So all samples that needed dilution 
were diluted to fulfil the DNA working concentration. Fixing the DNA concentration 
used in PCR was intended to lower the error differences between samples and keep 
all samples under as similar a set of conditions as possible. Additionally, a consistent 
and accurate dilution is important to make PCR and HRM results more accurate and 
interpretable across multiple experiments.  Many reagents used in the methods 
required dilution, such as the primers in the PCR HRM methods, with similar stock, 
though different final concentrations used in each assay. The accuracy of dilution is 
important to keep the PCR and HRM results more consistent. All the dilution were 
done according to the following formula: C1xV1=C2xV2. C1 equals the starting 
concentration, V1 equals the starting volume, C2 equals the desired concentration 
and C2 equals the desired volume to be produced (Mccormack et al., 2010). 
 
3.3.3 Polymerase Chain Reaction  
 
PCR, the primary method used for this study, produces billions of copies of the 
specific targeted DNA sequence, avoiding production of non-specific amplicons that 
may interfere with the results. Following primer design, PCR conditions are 
optimised to determine the most efficient conditions where the primers work and 
amplify at their best. 
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   3.3.3.1   Primer Design 
 
For each of the proposed SNPs, specific forward and reverse primers were 
designed using the Primer3 program to find a primer pair specific to each DNA 
template, targeting the desired gene sequence which contained the proposed SNPs of 
this study. Designing the primer to be sensitive and specific is important for the yield 
of the PCR product and the HRM results. Basically, the designed primers are the key 
for a good PCR amplification. 
Using the NCBI website (www.ncbi.nlm.nih.gov) I accessed the DNA 
sequence for all three proposed SNPs with the exact location of each SNP. Then 
using the Primer3 program (http://bioinfo.ut.ee/primer3-0.4.0/), I designed the 
primers. In this study all primers were designated to be around 20 bp in length and 
the DNA amplicon produced between 100 to 150 bps. All other parameters were left 
as defaults. Primers were also checked using Primer-BLAST. The primers designed 
for NCoA1 Polymorphism rs1804645 were:  
NCoA1 rs1804645 Forward Primer: GCCAACTTTGCTCCATCTCT (20bp) 
NCoA1 rs1804645 Reverse Primer: AGTCACCAGACATGAAGGCC (20bp) 
Product size: 126 bp  
 
• The primers designed for NCoA3 Polymorphism rs2230782 were:  
NCoA3 rs2230782 Forward Primer: CCAAGAGTCCTCTGGGCTTTTATT (24bp) 
NCoA3 rs2230782 Reverse Primer: CCCTCAACACTGCTCTCCTTACTT (24bp) 
Product size: 115 bp 
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• The primers designed for NCoA3 Polymorphism rs2076546 were:  
NCoA3 rs2076542 Forward Primer: GCAATACTGGTCTCGCACCT (20bp) 
NCoA3 rs2076542 Reverse Primer: TCAAACTCCATGGGAAGACC (20bp) 
Product size: 124 bp 
 
 3.3.3.2 PCR and Other Reagents 
 
To set up a PCR assay the following reagents are required: DNA template, 
nucleotides (dNTPs), DNA Taq polymerase, DNA primers (forward and reverse), 
MgCl, nuclease free water and buffer (typically Tris-HCL at a specified pH) 
(Gelfand, 1989). The suppliers for my reagents were: 
Polymerase and Buffer - Promega (Alexandria, Australia) 
dNTPs - New England Biolabs (Ipswich, MA, United States of America) 
MgCl2 - Promega (Alexandria, Australia) 
Primers - Integrated DNA Technologies (Baulkham Hills, Australia) 
SYTO9 - Thermo Fisher Scientific (Seventeen Mile Rocks, Australia) 
Agarose - Bioline (Alexandria, Australia) 
TRIS- EDTA - Sigma Aldrich (Castle Hill, Australia)  
 
   3.3.3.3 PCR Assay 
Following primer design, the basic PCR assay for this research was optimised 
and final reagent concentrations for DNA amplification were determined. For 
researchers wishing to replicate the work, complete assay details are available in 
Appendix B. Optimisation details are outlined in Appendix C. 
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3.3.3.4 PCR Thermal Cycles 
In addition to developing specific reagents for PCR, thermal cycling conditions 
for the reactions for each SNP amplification reaction were also determined. These 
conditions are outlined below. 
 
For NCoA1 Polymorphism rs1804645: 
Temperature (°C) Time of Cycles (Mins) Number of Cycles 
95 1:00 1 
95 
61 
72 
0:15 
0:15 
0:30 
35 
72 7:00 1 
 
For NCoA3 Polymorphism rs2230782: 
Temperature (°C) Time of Cycles (Mins) Number of Cycles 
95 1:00 1 
95 
66 
72 
0:15 
0:15 
0:30 
35 
72 7:00 1 
For NCoA3 Polymorphism rs2076546: 
Temperature (°C) Time of Cycles (Mins) Number of Cycles 
95 1:00 1 
95 
56 
72 
0:15 
0:15 
0:30 
35 
72 7:00 1 
 
 
Chapter 3: Research Design 49 
 
3.3.4 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis was developed between the 1960s and 1970s, and 
is an easy, yet precise, and widely used technique for separating DNA or RNA 
fragments by size based on the rate of movement while under the influence of an 
electric field. Once separated, DNA and RNA can be used for visualization and 
purification. 
The higher the voltage used in electrophoresis, the less time the separation will 
consume, but too high voltage may cause the gel to melt and reduces discrimination 
power for fragments of similar size. DNA is negatively charged, due to its phosphate 
molecule, and so will move towards the positive electric terminal, with large 
fragments moving through the gel more slowly, enabling the identification of 
specific PCR products or restriction fragments when the gel is exposed to the dye’s 
reporter wavelength (Brody et al., 2004; Jeppsson et al., 1979). In this project, a 
picture under UV light was taken in order to read the results (Figure 3.5). 
 
 
Figure 3.5. PCR Results Using Agarose Gel Electrophoresis. In both figures A and B, 
the ladder in well number 1 is clear with fully separated bands in the first well (size in base 
pairs indicated). Figure 3.5.A represents one of the results of this study’s PCR run during the 
process of PCR optimization. The ladder in the first well is followed by 4 duplicated DNA 
samples and then a duplicate water sample. More than one bright band appears clearly in 
each DNA sample run representing the presence of non-specific bands produced during the 
PCR. In one of the water samples (well number 10) there is a DNA band that looks like the 
desired amplicon, indicating the presence of DNA contamination while loading the samples 
on the gel, or in the original PCR. There is no presence of any bands in the other water 
sample (well number 11), indicating that that none of the stock reagents or the reaction itself 
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were contaminated, though the result was still considered unreliable. This is one of the 
reasons I duplicated each sample in experimental assays. Figure 3.5.B represents the results 
of the same PCR run after PCR optimisation. The ladder in the first well is followed by 4 
duplicated DNA samples and then a duplicated water sample. One bright band appears 
clearly in each DNA sample run without any non-specific bands. There is no presence of any 
bands in the water samples, ensuring that all reagents and the reaction were not 
contaminated. 
 
3.3.5 High Resolution Melting 
 
High Resolution Melting (HRM) is a simple, rapid and low-cost sequence 
screening method (also referred to as post PCR melt analysis) used for genotyping 
and mutation scanning (Reed et al., 2007).  Its main mechanism, melting curve 
analysis in conjunction with real-time PCR, was introduced in 1997 (Lay et al., 
1997; Ririe et al., 1997). 
The advantage of HRM is that PCR amplification and genotyping analysis are 
performed within the same tube or plate without any post-PCR processing, helping to 
minimise the potential for various forms of error, including contamination of future 
PCRs (Wittwer et al., 2003). In this study, HRM was carried out in a Qiagen RotorQ 
instrument, which has superior HRM capabilities to conventional plate based PCR 
machines, due to all samples being contained in a single heating chamber, 
minimising variation and providing more reliable analysis.   
After obtaining billions of copies of my desired specific target DNA sequence 
(PCR Product), HRM is used to give the genotype of each sample by measuring the 
melting curves (Figure 3.6) of double stranded DNA using its fluorescence from a 
saturating dye (SYTO9). In the HRM experiments for this study, two samples with 
known genotypes were used as positive controls for each experimental run, 
specifically the wild type and heterozygous genotype. Where possible, a homozygote 
mutation would also be used, but for my SNPs, due to their genotype rarity, this was 
not possible prior to commencement of experiments. For accurate results, each 
sample was duplicated, and to ensure that all reagents and the reaction were not 
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contaminated, a duplicated water sample (i.e. no DNA sample) was used as a 
negative control in each HRM run. 
 
Figure 3.6. HRM Normalized Melt Curve with a Single Point Mutation.  X-axis: 
Temperature °C; Y-axis: Normalized fluorescence. This figure shows the variation in 
melting curves of the three genotypes possible from a single nucleotide polymorphism. 
These are specifically: wild type (green colour), heterozygous (blue colour), and mutant 
homozygous (dark red colour). The curve demonstrates the sharp decrease in fluorescence 
when the double-stranded DNA (A) melts into its single-stranded (B) form under the 
influence of increased temperature. Adapted from: (Thermofisher, accessed  2017).  
 
   3.3.5.1 HRM Thermal Cycles 
For NCoA1 Polymorphism rs1804645: 
Temperature (°C) Time of Cycles (Mins) Number of Cycles 
95 10:00 1 
95 
66 
72 
0:15 
0:20 
0:30 
40 
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For NCoA3 Polymorphism rs2230782: 
Temperature (°C) Time of Cycles (Mins) Number of Cycles 
95 10:00 1 
95 
64 
72 
0:15 
0:25 
0:30 
40 
 
For NCoA3 Polymorphism rs2076546: 
Temperature (°C) Time of Cycles (Mins) Number of Cycles 
95 10:00 1 
95 
58 
72 
0:15 
0:20 
0:30 
45 
 
    3.3.5.2 HRM Positive Controls 
 
After optimising the HRM, ten unrelated DNA samples (samples used were not 
any of this study’s population samples) were analysed using HRM analysis in order 
to find a sample for each of the three different genotypes to set them as positive 
methodological controls. After identifying potential positive controls, each one was 
sequenced using Sanger sequencing in order to confirm a precise accurate genotype. 
Then, within each HRM run the positive controls were added and genotyped as well. 
The HRM positive controls were used as a genotype reference, where each 
genotyped sample results for experimental samples were compared to the positive 
controls results in order to enable reading of the genotype. Normally three positive 
controls: wild type, heterozygous, mutant homozygous would be picked and used in 
every HRM run. The “wild type” represents the normal DNA sequence that doesn’t 
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contain the SNP on either parental chromosome. The “heterozygous” represents the 
presence of the SNP on one of the parental chromosomes. The “homozygous” 
represents the presence of the SNP on both parental chromosomes which usually has 
a rare frequency compared to the “wild type” and the “heterozygous” genotypes. 
Unfortunately in all the proposed SNPs of this study, the “homozygous” genotype 
couldn’t be found as a positive control or in any of this study's population samples. 
 
           3.3.5.3 HRM Results 
 
HRM can provide semi-quantitative results of the PCR product as well as the 
genotype of each sample making it easier to follow up with each sample during each 
step. The results provided by HRM are: PCR curves, normalized melt curves, melt 
curves analysis and genotypes calling and confidence. In the PCR curve results 
(Figure 3.7), normally curves starts increasing from 0 to 100 normalised fluorescence 
units representing the increased copies of the desired DNA fragment due to 
amplification.  
 
Normalized melt curves (Figure 3.8), are the reverse of the PCR curves, and 
they decrease because with the melting of the double stranded DNA, the SYTO9 
loses its fluorescence. The different types of curves present indicate the different 
genotypes in the samples. In the melt curve analysis (Figure 3.9), peaks represent 
different genotypes where a single peaked curve is a wild type genotype and a double 
peaked curve is a heterozygote genotype. In the genotypes calling and confidence 
display (Figure 3.10), the machine's software can read the genotypes approximately 
by comparing each sample results to the designated genotypes of the positive 
controls. The results taken from the instrument can be presented in many different 
ways for data analysis and experiment quality checking, as the following figures: 
 
 
Chapter 3: Research Design 54 
 
 
Figure 3.7. HRM Quantitative Results of PCR Cycles. This figure, presenting the results 
of one experimental PCR, measures the normalised percentage of fluorescence (y-axis) of 
SYTO9 dye with the progression of PCR cycles (x-axis).  Each sample has a colour code to 
make it easier to follow the amplification of each sample. Three types of curves are 
presented in this figure. Number 1 curves show efficient production of PCR product, the 
variance between them depends on the quality of the DNA in each sample. Number 2 curves 
show a very late PCR, due to bad DNA quality, pipetting or machine error, quantitating the 
samples and running them again is the best way to figure out the cause and read their 
genotypes. Number 3 curves show zero amplification, which may be due to more extreme 
forms of the same errors causing type 2 curves, or is expected for negative controls. For type 
three curves in tubes containing DNA the samples underwent a DNA quantitative check 
using the NanoDrop machine to check the purity and quality of the DNA then were run 
again. 
 
Figure 3.8. HRM Normalised Melt Curve. This figure, presenting the results of one 
experimental PCR, measures the normalized fluorescence (y-axis) against temperature (x-
axis).  From the variation in melting profile of each genotype I can discern different 
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genotype curve clusters (1 and 2). Each sample is compared to the +ve controls samples used 
to determine its genotype, which was present for each experiment. 
 
Figure 3.9. HRM Melt Curve Analysis. This figure, presenting the results of one 
experimental PCR, measures the derivative of fluorescence with respect to temperature 
(dF/dT) (y-axis) against temperature (x-axis).  From the variation in melting profile of each 
genotype I obtain different genotype peaks. The samples with 1 peak represent a 
homozygous genotype, while the samples with two peaks represent a heterozygous genotype. 
Different homozygous genotypes (not pictured here) have single peaks displaced left or right 
depending on their specific melting temperature. 
 
 
Figure 3.10. HRM Genotypes Calling and Confidence. This figure, derived from an 
experimental PCR, represents the software automated calling option in the analysis of the 
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genotype of each sample. It is performed by combining the results of the melting curves and 
instructing the software as to the identity of the positive controls. The software then gives the 
genotype and the confidence percentage (acceptable confidence cut off > 70%) by 
comparing each sample to the +ve controls. Any variation that the program was not able to 
read was subject to manual genotyping if possible or PCR of the sample repeated if 
necessary. 
 
3.3.5.4 HRM as a first choice method and limitations 
 
There are many different methods for genotyping a SNP including RFLP, real 
time PCR, Sanger sequencing and HRM. In order to pick the best method to be used 
in this study, there was a comparison between the methods according to their 
mechanisms, protocol and steps, reagents and how often they are used in recent 
studies.  
The RFLP method requires the presence of restriction enzymes, which are 
specific for the SNP location on the DNA fragment, which digest all the DNA with 
the SNP present, producing DNA fragments. The main problem with RFLP is that 
there isn’t a specific restriction enzyme for every single SNP, which leaves the 
researcher unable to use it with some SNPs. Another disadvantage of RFLP is that it 
requires a post-PCR step to set up the digestion and a post digestion step which 
involves running the digested DNA fragments on agarose gel in order to read the 
results. None of the RFLP results are quantitative and less feedback on experimental 
problems is available. 
Real time PCR is based on the production of specific colours of fluorescence 
based on the dye associated with an allele specific probe. It requires a fluorescent dye 
that gives fluorescence when it is released from the allele specific probe during 
incorporation into a new double stranded DNA fragment, or when bound as part of 
that new fragment and is detected under a suitable light source. This method is better 
and easier than RFLP as it gives quantitative results and each sample can be followed 
up to know exactly what is happening in each tube. The real time PCR based 
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methods do require allele specific probes which come in different types like 
hydrolysis probes, hybridisation probes and molecular beacon probes. These probes 
can be expensive and have their own problems of optimisation and specificity, like 
PCR primers. 
Sanger sequencing, as described more fully below, is the gold standard method 
of determining genotype, as each base in the target amplicon can be precisely 
identified. However, it requires post-PCR processing, like RFLP, and is perhaps the 
most expensive method of genotyping available. Its precision and high level of 
feedback of result reliability does make it an excellent choice for error detection. 
The HRM method, which was my choice to be used as the main genotyping 
method for this study, requires no restriction enzyme or any probes. It is an easy, low 
cost, and its software is user friendly.  The key factor of HRM is the saturated dye 
SYTO9 which fluoresces under the UV light when binding to double stranded DNA. 
HRM has a high sample load support that contains 72 wells per unit in each run. 
HRM does not require any post-PCR steps. In fact, all the samples can be genotyped 
from the different forms of results that the machine gives. HRM does have 
drawbacks in that it is highly sensitive to variations in initial PCR conditions, as well 
as variations within PCR as they are performed. This necessitates the use of positive 
control samples in each run, so that any distortion of let curves due to contaminating 
substances or machine variation can be accounted for. No Sanger sequencing is 
needed after a HRM run, but around ten randomly picked samples from each 
genotype were subject to sequencing to be sure that my genotype results reading was 
accurate. 
 
3.3.6 Sanger Sequencing 
 
DNA sequencing is used to determine the nucleotide sequence in DNA for 
highly accurate determination of gene makeup (Sanger et al., 1977). It includes any 
method or technology that is used to determine the order of the four bases, adenine, 
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guanine, cytosine, and thymine. In this research, I used the Sanger DNA sequencing 
method. This method is based on the addition of specific primers (of known 
sequence) to the DNA template to be sequenced, which provides a starting point for 
DNA synthesis (Franca et al., 2002). Following the addition of DNA polymerase and 
free nucleotides, dNTPs, the catalytic polymerization of dNTPs onto DNA occurs 
(Franca et al., 2002). The polymerization will stop after the incorporation of a 
modified nucleotide, ddNTP, with a specific fluorescent colour for each base, which 
is also included in the reaction, into the growing DNA chain (Franca et al., 2002). 
Samples were then examined using high resolution Sanger sequencing polymer gels 
(specifically the POP-7 polymer produced by Life Technologies) in an ABI 3500 
sequencer (Life Technologies) in order to read the DNA sample sequence. This 
method was performed following HRM on a proportion of samples from each 
genotype to confirm the results of HRM and specify any observed changes in the 
base sequence. Sequencing was also done to obtain positive controls for each 
genotype prior to commencing HRM (Figure 3.12). 
 
 
Figure 3.12. Results Curves of the Sanger Sequencing Method. This figure is derived 
from primary results from this project, by taking a screen shot of sequence data displayed on 
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the Chromas software and derived from ABI 3500 sequence traces (Thermo Fisher). Each 
peak presented in this figure represents a single base position in each strand of the DNA. 
Each of the 4 bases A, T, G and C has a code colour, which are red, green, black and blue 
respectively, for manual reading. The SNP position can be determined by finding its 
surrounding bases. The machine reads the sequence results and presents them on top on each 
peak; if the software cannot assign a specific base identity then it is represented by letter 
“N”.  In example A we can see that at the location of the SNP there is one clean peak 
representing a G base [black colour], which means that both bases of both DNA strands 
carry G base, which is a homozygous genotype. In example B, at the SNP position we can 
see two peaks representing C [blue colour] and G [black colour] bases, which mean that it is 
a heterozygous genotype. 
 
3.3.7.1 Sanger Sequencing Protocol 
 
Step 1: Exo-SAP-IT Cleanup  
Cycling Protocol: 
Temperature (°C) Time of Cycles (Mins) Number of Cycles 
37 15:00 1 
80 15:00 1 
4 ∞ - 
Step 2: BDT Reaction 
Cycling Protocol for BDT Reaction 
Temperature (°C) Time of Cycles (Mins) Number of Cycles 
96 1:00 1 
96 0:10 
30 50 0:50 
60 4:00 
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4 5:00 1 
10 5:00 1 
4 ∞ - 
Step 3: Ethanol Precipitation 
Step 4: Load samples into 3500 Genetic Analyser 
 
3.3.7.2 Sanger Sequencing Results for Positive Controls 
 
After genotyping all the positive control DNA samples for each of the 
proposed SNPs, I sequenced them to be sure of their genotyping results. For SNP 
rs1804645, only two positive controls were found MB144 as wild type (C/C) and 
MB146 as heterozygote (C/T) (Figure 3.13). For both positive controls, the reverse 
sequencing was not readable due to the excessive presence of noise alongside the 
peaks; however I still can read the results from the forward sequencing of each 
positive control.  For SNP rs2230782, only two positive controls were found MB143 
as wild type (G/G) and MB129 as heterozygote (C/G) (Figure 3.14). For SNP 
rs2076546, only two positive controls were found MB140 as wild type (T/T) and 
MB147 as heterozygote (C/T) (Figure 3.15). At least ten attempts at sequencing were 
made to obtain both forward and reverse sequences for all the positive controls. I was 
not able to determine an exact cause for the signal loss and both alleles for rs1804645 
should have been readable in both directions, despite the small amplicons required 
for HRM. As a result, a separate PCR would need to have been developed to allow a 
clean read in both directions.  Unfortunately, due to time constraints, this was not 
possible. 
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Figure 3.13. Sanger Sequencing Results for rs1804645 Two Positive Controls. This 
figure shows the forward (F) sequence results for DNA samples MB 144 and MB 146, C/C 
and C,T respectively. 
 
 
 
Figure 3.14. Sanger Sequencing Results for rs2230782 Two Positive Controls. This 
figure shows the forward (F) and reverse (R) sequence results for DNA samples MB 143 and 
MB 129, G/G and C/G respectively. 
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Figure 3.15. Sanger Sequencing Results for rs2076546 Two Positive Controls. This 
figure shows forward (F) and the reverse (R) sequence results for DNA samples MB 140 and 
MB 147, T/T and C/T respectively. 
 
3.4 DATA ANALYSIS 
 
To determine whether any significant difference in polymorphism frequencies 
occur between the case and control populations, results of allele and genotype 
frequencies were compared using the Chi-square method. This analysis is based on 
the equation stated below, comparing the case population (observed frequencies) to 
the control population (expected frequencies) and determining if the difference 
between them is of sufficient magnitude to exceed the threshold probability for my 
study. For my research I performed a single comparison for each polymorphism, so 
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the significance threshold, also called alpha value, was set at level 0.05. Analysis was 
performed using the SPSS statistical package. 
There is an additional test that was performed on each population following 
successful genotyping, a Hardy-Weinberg Equilibrium (HWE) test. The HWE test is 
a Chi-square based test to determine whether the obtained population genotype 
frequencies differ from the ideal distribution that should be found in a randomly 
mating population. The ideal distribution is given by the Hardy-Weinberg equation 
of p2+2pq+q2 =1 where p and q represent the frequencies of the two alleles of a 
polymorphism (Guo et al., 1992; Mayo, 2008). 
The HWE test was used in this study primarily to detect the effect of bias in 
genotyping. If populations significantly differ from the ideal HWE population, it is a 
sign that there could be bias in the genotyping of that population, or else that some 
other factor is altering allele frequency in the tested group. 
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Chapter 4: Results 
 As outlined in the last chapter, optimised conditions for genotyping three 
SNPs, NCoA1 rs1804645, NCoA3 rs2230782, and NCoA3 rs2076546, were 
developed and then BC cases and controls were genotyped. After genotyping the 
population samples for each of the three proposed SNPs, several different statistical 
analysis tests were performed to determine if there was any association between the 
identity of the SNPs and the risk of developing breast cancer using Chi-Square 
analysis. An additional test, the Hardy-Weinberg Equilibrium, was performed to 
ensure that overall genotyping was of high quality. Finally, for the available BC risk 
factor data, analysis was performed using Chi-Square, T-Tests, logistic regression 
and nominal regression to determine the impact of these factors on any association 
between the tested polymorphisms and breast cancer.  
A power calculation analysis was performed to estimate the sample size 
required to give accurate results regarding the candidate SNPs, depending on the 
strength of any influence the SNPs might have on breast cancer susceptibility. This 
calculation was performed with G*Power v3.1.9.2.  
Although the population sample number for this study was fixed by the size of 
the available pre-recruited cohort and the calculation was effectively post-hoc, the 
power calculation shows that this population has the ability to give good power 
outcomes for effect sizes between medium and small (~80% power at w=0.2).This 
indicates that, despite the relatively small population size, the research should be able 
to detect relatively subtle genetic effects on breast cancer susceptibility. 
Although larger studies derive more power from their increased population 
sizes, it is worth considering that larger studies have a problem where the more 
women included in a study it becomes harder to appropriately control the large 
number of risk factors that affect breast cancer. This can lead to bias in the levels of 
specific risk factors, which can also lead to skewed and inconclusive outcomes.  
By contrast, in a disease with many risk factors, a small number of well 
controlled individuals can give more precise outcomes compared to single gene or 
whole-genome studies that include very large population numbers but may include 
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groups of diverse lifestyles and ethnicity where contradictory effects may distort the 
results obtained. 
The case and control populations utilised in this study show good similarities 
of risk factors, with the potential power of the populations relatively good, despite 
their small size. 
Table 4.1 contains the Chi-square values and the P-values for each of the 
candidate SNPs NCoA1 rs1804645, NCoA3 rs2230782, and NCoA3 rs2076546 for 
the genotype and alleles analysis. It also shows for the frequency counts and 
percentages for the genotypes and alleles of each proposed SNP. While there are 
some observed differences between the frequencies of the candidate SNPs, at around 
5% for genotypes and 1-3% for alleles, none of these differences proved to be 
significant, with only rs1804645 displaying a P-value less than 0.1. 
 
Table 4.1: Chi-Square and P-value for Genotypes and Alleles for the Candidate  
 
SNPs and the HWE results. 
 
 Chi-square and P-value HWE 
NCoA1 
rs1804645 
Genotypes Alleles  
 CC CT TT C T P-
value 
Chi-
Square
Cases 202 56 0 460 56 0.050 3.8236 
(n=258) (78.3%) (21.7%) (0%) (89.1%) (10.9%)   
Controls 155 28 0 338 28 0.262 1.2558 
(n=183) (84.7%) (15.3%) (0%) (92.3%) (7.7%)   
 Genotype Analysis Allele Analysis   
 χ2 =2.85 p=0.091 χ2=2.55 p=0.11   
 Chi-square and P-value HWE 
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NCoA3 
rs2230782 
Genotypes Alleles  
 GG GC CC G C P-
value 
Chi-
Square
Cases 227 44 0 498 44 0.145 2.1155 
(n=271) (83.8%) (16.2%) (0%) (91.9%) (8.1%)   
Controls 174 26 0 374 26 0.325 0.9665 
(n=200) (87%) (13%) (0%) (93.5%) (6.5%)   
 Genotype Analysis Allele Analysis   
 χ2 =0.9 p=0.329 χ2=0.88 p=0.349   
 
 
  
 Chi-square and P-value HWE 
NCoA3 
rs2076546 
Genotypes Alleles  
 TT TC CC T C   
Cases 222 32 0 476 32 0.283 1.1479 
(n=254) (87.4%) (12.6%) (0%) (93.7%) (6.3%)   
Controls 163 20 0 346 20 0.434 0.6114 
(n=183) (89.1%) (10.9%) (0%) (94.5%) (5.5%)   
 Genotype Analysis Allele Analysis   
 χ2 =0.28 p=0.595 χ2=0.26 p=0.601   
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Hardy-Weinberg equilibrium analysis was performed and the results are 
presented in table 4.2. For each candidate SNP BC cases and controls, the P-value 
and Chi-square was calculated to see if they showed Hardy-Weinberg equilibrium or 
not. The significance threshold was set to equal to or less than 0.05. No significant 
deviation from Hardy-Weinberg equilibrium was observed for most of the 
polymorphisms examined in the study populations, with the exception of the SNP 
rs1804645 in the breast cancer case cohort, which equalled the significance threshold 
when rounded to two significant figures. This is a potential sign that there may have 
been bias in the genotyping for this SNP, but since the sequencing confirmation 
showed no discordance with the HRM results, the lack of the homozygous mutant 
genotype may be the cause of the small changes in population distribution affecting 
the HWE outcome. However, it is unlikely that this is a potential issue for the 
reliability of study results. 
Table 4.2: Hardy-Weinberg Equilibrium for Biallellic Single Nucleotide 
Polymorphism. 
SNP P-value Chi-Square 
NCoA1 
rs1804645 
BC cases 0.0505 3.8236 
BC controls 0.2624 1.2558 
NCoA3 
rs2230782 
BC cases 0.1457 2.1155 
BC controls 0.3255 0.9665 
NCoA3 
rs2076546 
BC cases 0.2839 1.1479 
BC controls 0.4342 0.6114 
 
 
An independent sample T-Test was performed to study whether there were 
differences between the distributions of some BC risk factors: BMI, age of 
menarche, number of breastfed children and the number of pregnancies (Table 4.3.A) 
and with the detailed characteristics of the T-Test performed shown in Table 4.3.B. 
This test was only performed for a subset of the population for which data was 
available, only 105 BC cases and 85 controls. Minor differences in the characteristics 
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can be seen, though only BMI shows a significant difference, with breast cancer 
cases having higher BMI than controls. 
 
Table 4.3 A: T-Test for Breast Cancer Factors between cases and controls. 
 
Characteristic T df Significance 
Body Mass Index 2.01 178 0.046* 
Age at menarche 0.244 181 0.808 
Number of breastfed children 1.066 179 0.288 
Number of pregnancies -0.646 183 0.519 
 
 
 
Table 4.3 B: Characteristics of the Populations Used in the T-Test. 
 
Characteristic Population N Mean Std. Dev. Std. Err. 
Mean 
BMI Case 97 26.33 4.55 0.462 
Control 83 24.96 4.58 0.504 
Age at Menarche Case 102 13.11 1.68 0.165 
Control 81 13.04 1.52 0.169 
Number of 
breastfed children 
Case 103 1.60 1.42 0.140 
Control 78 1.85 1.65 0.187 
Number of 
pregnancies 
Case 105 2.66 1.73 0.169 
Control 80 2.84 2.07 0.231 
 
 
Another Chi-Square test was performed to study the relationship between each 
of the proposed SNPs and the case control study and the following BC factors: pre 
and post-menopausal status, usage of HRT during their lifetime, smoking during their 
lifetime, those who ever smoked and those who ever used HRT (Table 4.4). None of 
these factors were statistically significant, and only those who ever smoked (in 
addition to the previously identified case-control P-value for rs1804645) showed a P-
value below 0.1. 
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Table 4.4: Chi-Square Test P-values for Candidate SNPs Between Cases and 
Controls and BC Risk Factors by Genotypes. 
 
SNPs Case Control Menopause HRT Smoking 
Ever-
Smoked 
Ever-
HRT 
rs1804645 0.091 0.828 0.968 0.224 0.084 0.531 
rs2230782 0.329 0.110 0.164 0.612 0.322 0.153 
rs2076546 0.595 0.828 0.550 0.884 0.674 0.294 
 
 
I compared the counts of pre- and post-menopausal women, HRT status of 
participants (current, previously used HRT, never used HRT), those who ever used 
HRT, smoking status (current, ex-smoker or never smoker) and those who ever 
smoked between cases and controls (Table 4.5.A). The characteristics of the HRT 
(Table 4.5.B), smoking (Table 4.5.C) and for those ever smoked (Table 4.5.D) are 
displayed in the aforementioned tables. Each of these three characteristics showed 
significant differences between cases and controls. It can be seen that there is a 
significant shift in the numbers of cases who are current and previous users of HRT 
compared to controls, while the proportion of those who never used HRT remains 
similar in both populations. In terms of smoking, it can be seen there is a greater 
proportion of the breast cancer cases who have ever smoked, and the percentage 
distribution of previous and current smokers is also altered between cases and 
controls. 
 
 
Table 4.5 A: Chi-Square Test P-values for BC Factors between Cases and Controls. 
 
 Menopause HRT Smoking Ever-Smoked Ever-HRT
Case 
Control 0.187 0.04* 0.023* 0.018* 0.888 
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Table 4.5 B: Chi-Square Test for HRT Status between Cases and Controls. 
 
Population HRT Status Totals 
Never Current Ex 
Case 56 10 38 104 
(53.8%) (9.6%) (36.5%) (100%)
Control 44 21 17 82 
(53.7%) (25.6%) (20.7%) (100%)
 
 
Table 4.5 C: Chi-Square Test for Smoking Status between Cases and Controls. 
 
Population Smoking Status Totals 
Never Current Ex 
Case 46 17 43 106 
(43.4%) (16.0%) (40.6%) (100%) 
Control 51 5 28 84 
(60.7%) (6.0%) (33.3%) (100%) 
 
 
Table 4.5 D: Chi-Square Test for Ever Smoked Between Cases and Controls. 
 
Population Ever Smoked Totals 
Never Smoker 
Case 46 60 106 
(53.8%) (56.6%) (100%) 
Control 51 33 84 
(60.7%) (39.3%) (100%) 
 
An independent sample T-Test was performed to study the relationship 
between some of the BC risk factors with the candidate SNPs by genotypes. I 
compared the values for BMI, age of menarche, age at menopause, and the number 
of breastfed children within the proposed SNPs by genotypes (Table 4.6) where only 
in SNP rs1804645 the BMI showed significance (0.002). The T-Test was performed 
on only some of the risk factors as the test is only able to measure differences for 
continuous variables and is not suitable for the remaining categorical variables in the 
study. 
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Table 4.6: T-Test for Breast Cancer Factors Between Proposed SNPs by Genotypes. 
 
SNPs Characteristic t Df Significance 
rs1804645 
Body Mass Index -3.17 156 0.002* 
Age at menarche 0.550 158 0.583 
Menopause 0 152 1.000 
Number of breastfed 
children 
0.700 156 0.485 
rs2230782 
Body Mass Index 1.116 172 0.266 
Age at menarche -1.140 176 0.256 
Menopause -1.876 171 0.062 
Number of breastfed 
children 
-1.301 174 0.195 
rs2076546 
Body Mass Index -1.064 162 0.289 
Age at menarche -1.085 167 0.280 
Menopause 0.505 159 0.614 
Number of breastfed 
children 
1.182 164 0.239 
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Chapter 5: Discussion 
The many different classification types of breast cancer (histologically and 
molecularly based) and the subtypes make it quite challenging to obtain a diagnosis 
to identify the use of specific treatments despite all the knowledge and development 
in breast cancer field acquired in the last few decades. In addition, the large number 
of risk factors affecting the initiation, progression and aggressiveness of BC disease 
plays an important role in disease aetiology, and breast cancer is further divided into 
a familial or sporadic breast cancer each of which has specific treatment 
considerations. Since a breast tumour can be benign or malignant, can be hormone 
receptor positive or negative and can be affected by many factors; in which the 
diagnosis and treatment are dependent, anything that could affect the breast cancer 
types, subtypes or impact of risk factors would have a major effect on the future of 
every single breast cancer patient. In relation to any alteration that may affect a 
breast cancer tumour, this study, which is a complimentary to previous studies, was 
focused on single nucleotide polymorphisms where their presence could be one of 
the factors affecting breast cancer susceptibility. Since normal breast tissue function 
is hormonally dependent, mainly on estrogen and progesterone, this study’s approach 
and aims were to examine polymorphisms affecting the estrogen hormone receptor 
pathway, specifically their coactivators (NCoA1 and NCoA3). 
The results of this study could be influenced by the different types, 
classifications and heterogeneity of breast cancer. However, this study was focused 
on the candidate SNPs and the available data of the participating women did not 
include sufficient detailed information about the type, stage and severity of breast 
cancer to take these into consideration. This was a limitation of the study, which did 
not allow the examination of how the different classifications and heterogeneity of 
breast cancer on the results obtained. This information would be useful to see if each 
candidate SNP had no effect, was protective or indicative of a more severe effect in 
the different stages and types of this disease. Due to this limitation, I recommend 
future studies to collect such data and study the relationships between all factors and 
the presence of each SNP, under controlled conditions where each breast cancer type 
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should be grouped together. The data in this study however, can evaluate the effect 
of the candidate SNPs on general susceptibility to breast cancer. 
After genotyping all the populations for each candidate SNP, a Chi-Square test 
was performed to study the correlation between the presence of candidate SNPs and 
the risk of developing breast cancer. Statistical analysis of my data showed that the 
differences seen in genotype and allele frequencies in the case and control 
populations were not significant in all three examined SNPs in this study. All the P 
values for my candidate SNPs were greater than the 0.05 significance threshold (p = 
0.091 for rs1804645; p = 0.329 for rs2230782; p = 0.595 for rs2076546) (Table 4.1). 
This indicates that there is no association with overall breast cancer susceptibility in 
my population. 
None of the mutant homozygous genotypes were found in my population for 
any of the proposed SNPs (Table 4.1). This is primarily caused by two factors, first 
the relatively small size of the population used and secondly the rare frequency 
percentage of the alternative homozygote, previously observed at 0%, 0.17% and 
0.27% for rs1804645, rs2230782 and rs2076546, respectively (Table 5.1). 
All the P-values were quite far from the significance threshold (α =0.05) except 
for SNP NCoA1 rs1804645 with a P-value for the genotypes of 0.09. The 
interpretation for this result is that there is still no significant difference between 
cases and controls for this SNP, but the polymorphism may have a weak effect that 
may show significance if investigated in a larger population. The relatively small 
number of the population used in this research is one of the limitations of this study. 
It is possible that by using a bigger population, firstly the alternative homozygote 
genotype could appear amongst the samples which will improve the reliability of the 
general analysis and secondly the weak effect of rs1804645 in relationship with BC 
disease may be able to clearly shows a significant difference in the populations. 
It is possible also that weak non-significant P-value of rs1804645 could be due 
not to the small population size, but rather due to a gene linkage effect, where the 
presence of another polymorphism nearby that may alter the function of NCoA1 or 
has some other effect on breast cancer risk. Since close polymorphisms tend to be 
inherited together, we may be seeing the "shadow" of that polymorphism's effect. For 
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that reason, I hypothesise that the low, but non-significant result seen in my research 
might be due to the polymorphism being linked to another gene polymorphism which 
is a true risk factor for sporadic breast cancer. 
NCoA1 rs1804645 and NCoA3 rs2230782 were chosen for genotyping for 
being potentially functional polymorphisms and based on the severity of the amino 
acid change (Pro1272Ser) and (Gln586His) respectively, where functional SNPs 
change the type of amino acid leading to change in its function. Whereas, NCoA3 
rs2076546 is a synonymous polymorphism with no change in the amino acid 
structure (Thr960Thr) but still showed significance with breast cancer risk in familial 
cancers (Burwinkel et al., 2005). With the results of this study's analyses showing no 
significance, it is possible that the candidate SNPs have an effect on breast cancer 
risk, but it’s dependent on some other genetic factor or interaction with another BC 
risk factor.  
It is also possible that the candidate SNPs have a role in breast cancer but not 
in the risk of developing this disease. This study examines and measures the 
significance of these candidate SNPs for breast cancer susceptibility, but does not 
measure any effects on cancer development. Previous studies in familial BC have 
shown that the SNP rs2230782 had a protective effect amongst German, Polish and 
US populations (Burwinkel et al., 2005; Hartmaier et al., 2009). The SNP rs2076546 
has also been shown to have a protective effect, but this was only seen in German 
and Polish populations (Burwinkel et al., 2005; Hartmaier et al., 2009). Comparing 
those and my results, there is no significant difference to the data obtained by 
Burwinkel et al. However, for the rs2076546 SNP also examined by Hartmaier et al I 
observed a zero count in my C/C genotypes for this SNP. This is likely due to my 
small population size with Hartmaier and colleagues had a control population 
approximately six times the size of my population and found only 20 C/C 
individuals. 
Familial cancers have a common genetic factor within the family that strongly 
increases cancer susceptibility, and it is possible that the protective effects seen in the 
familial populations operate only when cells have begun partially altered growth. In 
the context of the more variable factors causing sporadic breast cancer, my candidate 
SNPs may not have a detectable effect. It is possible that these candidate SNPs might 
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have an effect on the progression of the cancer rather than susceptibility. This could 
be tested in a similar study, involving DNA taken from carriers of benign vs. 
malignant breast tumours or early vs. late stage breast cancer. 
None of the cases and controls for the three proposed SNPs show significant 
results for the HWB equilibrium, with the exception of the breast cancer cases for 
rs1804645, which were borderline (BC cases: p = 0.05 and controls: p = 0.26 for 
rs1804645; BC cases: p = 0.14 and controls: p = 0.32 for rs2230782; BC cases: p = 
0.28 and controls: p = 0.43 for rs2076546) (Table 4.2) indicating that all the results 
are within the acceptable and expected range. This indicates that the population was 
picked randomly and there was no significant genotyping bias. Looking at the result 
for the BC cases of NCoA1 rs1804645, the full P-value obtained was 0.05053352 
just above the significance threshold, but close enough when rounded down to be of 
concern regardless. There are several possible causes of this potential HWE 
violation.  
First, it is possible that there was bias in the genotyping of the samples, leading 
to a distortion in the results obtained. The HWE test for the control samples for this 
SNP, however, do not show HWE violation, and none of the samples that underwent 
secondary Sanger sequencing were shown to have a different genotype to their HRM 
results. While genotyping bias may still be occurring, it should not be strong enough 
to cause this significant a shift. 
Second, it is possible that rs1804645 has a sufficiently strong impact on breast 
cancer risk that it is causing a bias within the breast cancer population, causing risk 
modifying genotypes to appear more often than would be expected under Hardy-
Weinberg conditions. The interpretation of the result in this context is that all the 
breast cancer samples share the disease in common, causing them to shift away from 
the Hardy-Weinberg equilibrium. This explanation has some merit, in that rs1804645 
had the lowest significance value of any tested SNP, but these same results also 
indicate that whatever effect rs1804645 might have on breast cancer risk, it is not 
significant. 
Third, and perhaps most likely, there is the rarity of the rs1804645 
polymorphism to consider. No alternative homozygotes were identified in either the 
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breast cancer or control populations for rs1804645, and the presence of zero counts 
in any category does limit the effectiveness of the Chi-Square analysis on which the 
HWE test is based. The lack of alternative homozygotes also means that small shifts 
in the numbers of heterozygotes can cause significant changes in the result of the 
HWE test, as can be seen by a difference of only ~4% between the heterozygote 
frequencies between the case and control populations for rs1804645 resulting in the 
insignificant and significant HWE test results obtained. In future research, a larger 
base population should be used to allow the detection of some alternative 
homozygotes to eliminate this possibility for violation of HWE.  
These candidate SNPs still have the potential to influence hormone signalling, 
with the NCoA1 rs1804645 SNP previously demonstrated to affect response to 
Tamoxifen, one of the main treatments for breast cancer, via disruption of a glycogen 
synthase 3 (GSK3)β phosphorylation site (Hartmaier et al., 2012) and may also 
disturb the metabolism of amino acids by altering the transcriptional activity of the 
tyrosine aminotransferase gene (Tannour-Louet et al., 2014). The in vivo study by 
Tannour-Louet and colleagues provides strong evidence of the potential role of this 
SNP in breast cancer susceptibility, however, the connection to rs1804645 in humans 
is somewhat weaker with the study only examining a relatively small number of 
patients (n=16) (Tannour-Louet et al., 2014). 
Due to time limitation and despite the multiple attempts of sequencing done or 
modifications are made to obtain both forward and reverse sequences for all the 
positive controls, the reverse sequencing of the 2 positive controls (wild type and the 
heterozygote DNA samples) for NCoA1 SNP rs1804645 were not included in the 
thesis because the sequencing signal cuts off shortly before our SNP locus. The 
sequence was read in the forward direction only (Figure 3.13), and given the 
complete consistency between the forward sequencing and the clearly readable 
normalization melt curves along with the lack of time needed to optimise a new PCR 
to obtain bidirectional sequencing, the thesis had to be completed with the available 
data. What was blocking the reverse primers from sequencing my desired amplicon 
could be a reason for the potentially week results obtained for NCoA1 rs1804645 
SNP and would be interesting to detect in future studies. 
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Due to their actual and potential functional effects, my candidate SNPs may 
still have some role to play in breast cancer susceptibility by modulating, or being 
modulated by, other genes and metabolites in the hormone receptor pathway (Bhan et 
al., 2017). The protective effect seen in familial breast cancers for the 2 candidate 
NCoA3 SNPs rs2230782 and rs2076546 among the German and Polish population 
(Burwinkel et al., 2005) provides support   for further investigation. The population 
used in the study was large with 791 breast cancer cases and 1,644 controls, 
providing significant power, with such large numbers of samples preferable in 
genomic control-case studies. However the population used does not entirely 
correlate with this study as the work of Burwinkel et al was based on familial breast 
cancer. Having a larger study population would improve the accuracy of the results 
and may identify any significant effect on breast cancer susceptibility by the SNP. In 
order to maintain significance, study population cohorts should be very specifically 
controlled in sample recruitment with variations in risk factors present, which can 
distort the results obtained. 
There have been no other studies of these polymorphisms in breast cancer, but 
these SNPs have been examined in other disorders.. The NCoA3 rs2230782 SNP 
showed negative association with alcohol use and consumption disorders (Kovanen 
et al., 2010). This study was a case control study where ~512 cases were matched 
with controls for age and sex. Similar negative results were obtained with coronary 
artery disease in type 2 diabetes (Cresci et al., 2011). This study was based on 
genotyping 1043 patients (702 white and 175 black). The NCoA3 rs2076546 SNP 
has previously been shown to have negative association with dyslipidaemia (Yu et 
al., 2015). This study was based on a population of 529 Han Chinese individuals. 
Despite the negative results obtained in these studies, there is some potential for 
connection to breast cancer susceptibility since alcohol consumption and BMI are 
risk factors that affect the risk of developing sporadic breast cancer and the SNPs 
may affect metabolism associated with these factors in ways not detectable due to the 
design of these other studies. 
Thus, a secondary analysis using the SPSS program was performed to study the 
relationship between the presence of each SNP and the factors that may lead to BC 
based on hormonal influences. These included available data for age of menarche, 
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age of menopause, obesity (BMI), number of children, breastfeeding, smoking, and 
use of hormonal therapy. 
The risk factor data was not available for all the 447 samples of the population 
in order to perform the secondary analyses. I was able to pull out data for only 105 
BC cases and 85 controls. This smaller population size may affect the results 
obtained from secondary analyses by not enabling significant relationships to be 
detected or not giving reliable results. For future studies, it would be better to gather 
more complete data from the population and to perform the analysis with a bigger 
sample size allowing us to see how each SNP, each BC factor, and the cases and 
controls interact with the risk of developing breast cancer. The potential interaction 
of SNPs with specific risk factors like BMI underscores the need to produce very 
carefully controlled and matched populations to minimise the chance of overlooking 
or overstating the effect of a polymorphism. 
Replicating the statistical analysis using a bigger population will allow us to 
confirm the results and see whether my initial results are correct. Also with a larger 
population, the alternative homozygous genotype may appear amongst the samples, 
which will improve the results overall, as well as minimise the chances of problems 
with HWE as mentioned before. The genotype frequency results obtained in this 
study were similar to the Caucasian polymorphism frequency results available from 
HapMap, though with slight percentage differences which, provides evidence for the 
accuracy of my work.  
Table 5.1 HapMap frequencies for the candidate SNPs. 
 
 
NCoA1 rs1804645 
(NCBI, accessed 2017b) 
 
Genotypes 
 
Alleles 
 CC CT TT C T 
Controls 105 8 0 218 8 
(n=113) (92.9%) (7.1%) (0%) (96.5%) (3.5%) 
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NCoA3 rs2230782 
(NCBI, accessed  2017)  
 GG GC CC G C 
Controls 45 14 1 104 16 
(n=60) (75%) (23.3%) (1.7%) (86.7%) (13.3%) 
 
 
NCoA3 rs2076546 
(NCBI, accessed 2017c) 
 TT TC CC T C 
Controls 92 18 3 202 24 
(n=113) (81.4%) (15.9%) (2.7%) (89.4%) (10.6%) 
 
An independent sample T-Test was performed to study whether there were 
differences between the distribution of some BC risk factors between the case and 
control populations. Of all the parameters, only the BMI   showed significance with a 
P-value of 0.046 (table 4.3 A). Previous studies showed that BMI is associated with 
high risk of developing BC for post-menopausal women and pre-menopausal women 
with age above 35 (Cecchini et al., 2012). As a person’s BMI typically increases 
across their life, this category probably most closely reflects the true effect of BMI 
on breast cancer, as a cumulative risk over the person’s lifetime. 
It is possible that the difference in BMI between cases and controls observed 
represents a bias in recruiting of samples, and that BMI and related effects caused by 
estrogen release from adipose tissue may interact with some genetic factors in my 
population, obscuring true relationships to breast cancer risk. The limited population 
of individuals with in the population for whom BMI was available does mean that 
this may not apply to the population as a whole. The potential interaction of 
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candidate SNPs with specific risk factors like BMI does, however, underscore the 
need to produce very carefully controlled and matched populations to minimise the 
chance of overlooking or overstating the effect of a polymorphism. 
 The difference in the means of the BMI between the cases and the controls 
was interesting (table 4.3 B). None of the other factors showed any difference 
between the case and control populations; this may be a result of the small size of 
samples available for the analysis and depends also on the particulars of some of the 
factors that have complicated relationships with breast cancer risk. For example, 
when studying the correlation between the number of pregnancies or the number of 
breastfed children of the BC cases with the BC controls, the overall influence on risk 
depends on many characteristics. Some of those characteristics are whether the 
pregnancies happened earlier in life, or even during or after developing breast cancer, 
how long the children were breastfed and so on.  
Pregnancy and child birth have a lifetime BC risk effect on women. The time, 
the age and the conditions (for example, BC subtype that is developed) all play a role 
in defining whether it is a protective factor for breast cancer or not. A full term 
pregnancy before the age of 20 decreases the risk of lifetime BC by 50% for 
Estrogen Receptor positive BCs. However, this protective effect is decreased with a 
full term pregnancy after the age of 35 which is mostly associated with Estrogen 
receptor positive BC (Britt et al., 2007).  Maybe this is one of the reasons I didn’t 
find any association when comparing the controls and cases regarding total 
pregnancies. The longer the breastfeeding period is; the more protective BC effect 
amongst women. Breastfeeding parous women (with many offspring) are more 
protected against BC risk compared to uniparous or nulliparous women (Cancer, 
2002). My data lacks the proper resolution to determine the length of breastfeeding 
or the ages of childbirth, so these refinements to risk analysis were not available. The 
small size of the population that this analysis was done on was another potential 
reason for not seeing any significance for these factors.  
All this may have influenced the results to show no significance at all. Using a 
bigger and better characterised population would be the best to see if the results will 
be the same. Ideally, however, the two populations should also have similar profiles 
of risk factors, in that an association population should have as many risk factors for 
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the disease under study as equally distributed as possible. This was done by design in 
terms of age and sex, the two greatest risk factors for breast cancer, but the lack of 
differences between these risk factors for the available data suggest that my study 
population is well designed for most aspects of breast cancer risk. 
Since there was no significance in the first place between the proposed SNPs 
and the risk of developing BC then I was not expecting to see any significance while 
studying the correlation between the SNPs and BC factors (Table 4.4). But the P-
value (p=0.084) for “ever-smoked” in SNP NCoA1 rs1804645 was relatively low. 
This result may indicate some relationship between the candidate SNPs and smoking 
uptake, but without a mechanism to drive this association, the result appears to be a 
statistical anomaly.  
Only these three BC factors came up as significantly different between cases 
and controls; HRT status, smoking status, and those ever smoked with P-values from 
the Chi-Square test of 0.04, 0.023, and 0.018 respectively (Table 4.5 A). A nominal 
regression test to determine the influence of these factors in breast cancer risk was 
also undertaken and yielded similar results, as the significant factors were only the 
BMI, Smoking and HRT with slightly different results where p= 0.034, 0.027 and 
0.015, respectively. 
For the HRT status (Table 4.5 B), in both the cases and the controls, those who 
never took HRT are around 53% of each total number group. A big difference 
appears between the cases and controls for those are currently on HRT and those 
whom are HRT ex users with around 16% less in the current use category for cases 
and around 16% higher in the ex-cases compared to the controls. 
While a significant difference was detected for HRT status, these results do not 
likely reflect an important difference in breast cancer risk factors in my population. 
HRT is a therapy used for treatment of symptoms related to menopause. But once a 
patient is diagnosed with breast cancer, many women stop any hormonal therapy, 
primarily because breast function is hormonally dependent and the hormone estrogen 
is one of the main risk factors of developing breast cancer. It also has a role in the 
progression of the disease due its role in inducing breast cell proliferation and 
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continuing HRT while a breast cancer is present is often avoided, if only to minimise 
estrogen exposure of the tumour (Pritchard, 2001). 
When the current and ex HRT users were combined into one category as “ever 
HRT”, the results showed no significance at all (p= 0.888). This would indicate that 
the overall proportion of women who have or have not used HRT is equivalent in my 
two populations and any difference in the current use of HRT is due to the diagnosis 
of cancer, rather than the other way around.   
For smoking status (Table 4.5 C), in both the cases and the controls I see a 
difference in the percentages for those who never smoked, current smokers, and ex-
smokers. There is a known connection between smoking and breast cancer risk, and 
these differences may reflect the effect of smoking as a breast cancer risk factor 
(Vijayvergia et al., 2015). For the controls, the increased proportion of those who 
have never smoked may be expected, since with all the available information 
regarding the health effects of smoking, many people tend to try to avoid it as part of 
living a healthy life. In the cases, both those who never smoked and the ex-smokers 
have similar percentages at around 40% of each total number group with 16% as the 
current smoker’s percentage. The interpretation for these results for the large amount 
of ex-smokers could be due to doctors’ advice following a diagnosis of breast cancer, 
since smoking is one of the risk factors of breast cancer, so patients are advised to 
stop smoking as a part of the BC treatment process. The current smokers of the cases 
were still higher than those of the controls; this reflects the people who would not 
quit smoking, despite advice or knowledge of its negative effects on their health. 
Some reasons for continuation of smoking might be that some would find smoking a 
way of helping to relieve their emotional feelings and stress from the situation of 
having been diagnosed with breast cancer. Not forgetting also the strong addiction to 
smoking and how difficult it is to quit this habit for some individuals. 
When the current and ex-smokers are combined in one category as “ever 
smoked”, the difference between cases and controls still shows significance. Those 
who have ever smoked is higher in the cases than the controls (Table 4.5D). This 
may reflect the effect of smoking on breast cancer risk in my populations, though 
like childbearing and breastfeeding, the risk of smoking is dependent on timing and 
amounts of cigarette smoking across the lifetime. 
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Overall, this study did not identify a significant effect for the tested SNPs in 
breast cancer risk. Previous studies have shown an effect for some of the targeted 
SNPs in familial cancer and rs1804645 alters response to Tamoxifen (Kere et al., 
2012), and so potentially also modulates response to estrogen or its natural 
antagonists. With these factors in mind, future studies should include not only larger 
numbers to reliably obtain rare homozygotes, they could also be designed to take 
hormonal factors more specifically into account. Numbers of children, total time 
breastfeeding, use of hormone replacement therapy and other factors may need to be 
carefully factored into research populations to accurately determine what effect these 
SNPs might have on BC risk. 
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Chapter 6: Conclusions 
Two potentially functional SNPs (rs1804645 and rs2230782) and one 
synonymous SNP (rs2076546) were investigated in this study of sporadic BC to see 
if they showed association with disease susceptibility. This is the first study that has 
looked at those SNPs in sporadic BC. The candidate SNPs were selected as they had 
previously shown an effect on familial BC as mentioned in chapter two. 
In conclusion, the negative results showed no significance of any of the 
candidate SNPs with the risk of developing BC. However, these results are important 
for future studies and contribute toward the knowledge of breast cancer. For further 
studies replicating my work or looking at new SNPs, I advise using a bigger 
population as it would provide clearer results with less error. Despite their non-
association with the risk of sporadic breast cancer, it is interesting for further studies 
to investigate how these candidate SNPs would behave with the progression and 
advanced stages of breast cancer disease, or different breast cancer subtypes, 
particularly hormone dependent ones. Also investigating other SNPs in these genes 
could be beneficial, as well as taking the influence of hormonal risk factors into 
account by building populations with specific hormonal risk profiles. 
Genetics studies in BC have limitations due to the complexity of human DNA 
and the enormous number of identified and yet to be identified SNPs that occur in the 
genome. Data on the effects of SNPs can, however, accumulate over time. So the 
combination of this work with previous genetic studies and future studies may lead to 
a time where BC is more fully understood and hopefully prevented with new 
effective and targeted treatments.  
COM 
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Appendices 
Appendix A 
Ethanol Precipitation 
Ethanol precipitation is a method used to purify the DNA sample, removing 
any salt, protein, or residual buffer that the sample was stored in. It is also the last 
step in Sanger DNA sequencing. This method involves purifying by using ethanol to 
precipitate DNA from solution, followed by centrifugation to allow the DNA to be 
collected at the bottom of the centrifuge tube. The ethanol containing the dissolved 
contaminants can then be removed to leave only pure DNA behind (Feinberg et al., 
1983). The purity of the sample is of great importance since the methods in use for 
this research are sensitive and the presence of any contaminants in the sample, such 
as salt or protein may alter the results obtained. Contamination can even affect the 
PCR and HRM (a very sensitive method) to such a degree that they would be unable 
to produce a genotype for the samples. 
The ethanol precipitation protocol used in this study was as follows:  
Reagents:  
• 2µl of 3M Sodium Acetate  
• 2µl of 125mM EDTA  
• 100% Ethanol 
• 70% Ethanol 
Method: 
1. Label 1.5ml microcentrifuge tubes with the correct sample name. 
2. Add 2µl of sodium acetate & 2µl of 125mM EDTA into each 
microcentrifuge tube. 
3. Add DNA sample into the microcentrifuge tubes 
The volume of DNA depended on the volume of the DNA stock and the 
DNA concentration available. If there was a large volume of stock, 
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around 50µl was used. If there was a large volume but the DNA 
concentration is low then a larger amount might be used, 100µl or 
more.. If the stock DNA concentration was very low then the loss of 
DNA that can occur during precipitation meant that it was not worth 
cleaning and additional stock sources or fresh DNA from the blood 
stored in the -80 freezers was ought. 
4. Vortex for around 15 seconds 
5. Add 2.5 volumes of 100% Ethanol (relative to DNA and salt volume) 
into each tube. 
6. Vortex for around 15 seconds and then spin down briefly. 
7. Incubate at room temperature for 15 minutes. 
8. Centrifuge at 10,000rpm for 20 minutes (use 4 degree centrifuge). 
9. Remove supernatant and leave pellet in the tube. 
10. Rinse pellet by adding 70µl of 70% Ethanol. 
11. Vortex for around 15 seconds. 
12. Spin for five minutes at 10,000rpm (use 4 degree centrifuge). 
13. Remove supernatant carefully 
14. Dry pellets completely by using a vacuum centrifuge (5 min on high). 
15. Add 15µl of distilled water into each tube, then vortex and spin each 
tube. Sample can be immediately quantitated or left for up to 24 hours. 
 
 
Appendices 101 
Appendix B 
PCR Protocols 
The following tables represent the PCR protocols used in this study for each 
SNP: 
• Final PCR optimisation for NCoA1 Polymorphism rs1804645 wa s: 
 
Reagents concentration 
Reagent Volume (µl) (1 
reaction) 
[Stock] [Final] 
Buffer 2 5X 1X 
Forward Primer 1 10µM 1µM 
Reverse Primer 1 10µM 1µM 
dNTPs 0.8 10mM 800µM 
MgCl2 1.8 25mM 4.5mM 
Flexi Taq 
Polymerase 
0.2 5µM 0.1µM 
H2O 1.2 
DNA 2 20ng/µl 40ng (total) 
Final Vol 10 
• Final PCR optimisation for NCoA3 Polymorphism rs2230782 was:  
 
Reagents concentration 
Reagent Volume (µl) (1 
reaction) 
[Stock] [Final] 
Buffer 2 5X 1X 
Forward Primer 0.9 5µM 450nµM 
Reverse Primer 0.9 5µM 450nM 
dNTPs 0.8 10mM 800µM 
MgCl2 1.2 25mM 3mM 
Hot Taq Polymerase 0.05 5µM 25nM 
H2O 2.15 
DNA 2 20ng/µl 40ng (total) 
Final Vol 10 
• Final PCR optimisation for NCoA3 Polymorphism rs2076546 was:  
Reagents concentration 
Reagent Volume (µl) (1 
reaction) 
[Stock] [Final] 
Buffer 2 5X 1X 
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Forward Primer 0.9 5µM 450nµM 
Reverse Primer 0.9 5µM 450nM 
dNTPs 0.8 10mM 800µM 
MgCl2 1.5 25mM 3.75mM 
Hot Taq Polymerase 0.05 5µM 25nM 
H2O 1.85 
DNA 2 20ng/µl 40ng 
Final Vol 10 
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Appendix C 
PCR Optimisation 
Following the primer design, I undertook PCR assay optimisation. To obtain 
PCR conditions that favoured a good yield of amplification of my desired amplicons, 
the focus was on reagent concentration and cycling parameters. The denaturation and 
the extension step’s temperatures are usually the same in most assays, 95°C and 
72°C respectively. This is due to the physics of DNA denaturation and the optimal 
operating temperature of the DNA Taq polymerase. The annealing temperature is 
primer dependant; each designed primer has an approximate binding temperature 
which is based on its sequence. This temperature is, however, not always the perfect 
temperature for optimal PCR performance. The following formula allowed us to 
calculate the approximate binding temperature of forward and reverse primers, the 
average of which was set as the initial annealing step temperature for a given PCR 
assay, which was then tested during optimisation (Roux, 2009). This formula 
depends on the number of bases found in each primer fragment sequence as follows: 
T Primer = [(number of C & G)*4 + (number of A & T)*2] – 5  
T: temperature; C: Cytosine; G: Guanine; A: Adenine; T: Thymine; 5°C is 
removed for single base mismatch error. 
T annealing = 
T Forward Primer+T Reverse Primer
2  (Roux, 2009) 
 
• NCoA1 Polymorphism rs1804645 annealing temperature was: 
Annealing temperature calculation:  
SNP1 Forward Primer: 10 (G & C); 10 (A and T) 
Temperature = 10*4 +10*2 = 40+20 = 60 -5 = 55°C 
 SNP1 Reverse Primer: 11 (G & C); 9 (A and T) 
Temperature = 11*4 +9*2 = p44+18 = 62 -5 = 57°C 
 
 
Appendices 104 
Average of primer temperature = (55+57)/2 = 56°C set the annealing temperature at 
56°C. 
• NCoA3 Polymorphism rs2230782 annealing temperature was: 
Annealing temperature calculation: 
SNP2 Forward Primer: 11 (G & C); 13 (A and T) 
Temperature = 11*4 +13*2 = 44+26 = 70 -5 = 65°C 
 SNP2 Reverse Primer: 12 (G & C); 12 (A and T) 
Temperature = 12*4 +12*2 = 48+24 = 72 -5 = 67°C 
Average of primer temperature = (65+67)/2 = 66 set the annealing temperature at 
66°C. 
• NCoA3 Polymorphism rs2076546 annealing temperature was: 
Annealing temperature calculation: 
SNP3 Forward Primer: 11 (G & C); 9 (A and T) 
Temperature = 11*4 +9*2 = 44+18 = 62 -5 = 57°C 
 SNP3 Reverse Primer: 10 (G & C); 10  (A and T) 
Temperature = 10*4 +10*2 = 40+20 = 60 -5 = 55°C 
Average of primer temperature = (57+55)/2 = 56 set the annealing temperature at 
56°C. 
The aim of optimising the PCR is to get the PCR to work and produce a high 
quality pure product. In order to achieve this, I set up several PCRs with different 
range gradients of reagents. I started with a range of MgCl where we ran the PCR 
with different MgCl concentrations, between 4.25mM (1.7µl) and 6mM (2.4µl). This 
was followed with an agarose gel to check the strength and specificity of the PCR 
product and pick the best MgCl2 concentration to use. Then, I performed a 
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temperature gradient as well that ranged from five degrees lower and five degrees 
higher than the calculated annealing temperature. PCR products were again run on 
agarose gel to pick and fix the annealing temperature where the DNA band of my 
desired amplicon was clear and bright without any interference or presence of any 
other non-specific bands. If the initial PCR products were not good, then I increased 
the concentration of the primers and the dNTPs because the more primers and raw 
material (dNTPs) are present, the more likely it is to have a strong PCR product 
produced. It was preferable not to alter the DNA Taq polymerase concentration, and 
I attempted to use the lowest concentration which allowed the PCR to work, due to 
its expensive cost compared to other reagents.  Thus, alteration of other reagents and 
temperature until the best PCR conditions were reached was performed.
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Appendix D 
HRM Protocol 
 
After HRM optimisation, the PCR protocols necessary were slightly altered 
because after adding the SYTO9, HRM’s key reagent, the PCR product yield was 
affected. The following tables represent the HRM protocols used in this study for 
each SNP: 
• Final HRM optimisation for NCoA3 Polymorphism rs1804645 was:  
 
Reagents concentration 
Reagent Volume (µl) (1 
reaction) 
[Stock] [Final] 
Buffer 2 5X 1X
Forward Primer 0.9 10µM 900nM 
Reverse Primer 0.9 10µM 900nM 
dNTPs 0.8 10mM 800µM 
MgCl2 1.9 25mM 4.75mM 
Hot Taq 
Polymerase 
0.2 5µM 0.1µM 
SYTO9 0.5 5U/µl 2.5U 
H2O 0.8 
DNA 2 20ng/µl 40ng total 
Final Vol 10   
 
• Final HRM optimisation for NCoA3 Polymorphism rs2230782 was:  
Reagents concentration 
Reagent Volume (µl) (1 
reaction) 
[Stock] [Final] 
Buffer 2 5X 1X
Forward Primer 1 5µM 500nM 
Reverse Primer 1 5µM 500nM 
dNTPs 0.8 10mM 800µM 
MgCl2 1.2 25mM 3mM 
Hot Taq 
Polymerase 
0.05 5µM 25nM 
SYTO9 0.4 5U/µl 2U
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H2O 1.55 
DNA 2 20ng/µl 40ng total 
Final Vol 10 
• Final HRM optimisation for NCoA1 Polymorphism rs2076546 was:  
Reagents concentration 
Reagent Volume (µl) (1 
reaction) 
[Stock] [Final] 
Buffer 2 5X 1X
Forward Primer 1.2 5µM 600nM 
Reverse Primer 1.2 5µM 600nM 
dNTPs 1.1 10mM 1100µM 
MgCl2 1.5 25mM 3.75mM 
Hot Taq 
Polymerase 
0.05 5µM 25nM 
SYTO9 0.7 5U/µl 3.5U 
H2O 0.25 
DNA 2 20ng/µl 40ng total 
Final Vol 10 
 
 
Appendices 108 
Appendix E 
Sequence of Froward and Reverse Primers of each Candidate SNP 
For SNP rs1804645: 
AGATCATATACAATCCTGCTGCACAAATAACGTCTTAGTGAATGGAAAGCATTATTCCGA 
                                                                   
 
   61 GCTTACATTTATTTCATTGGTTTATGCTGAGATTTCTTGCCCTAGTTTAAGATACTAAAT 
                                                                   
 
  121 TTTTTCCATGCTCTGTTGAATGCGATATTTGTAAATATATTGCCTGACACAAGACAAGGC 
                                                                   
 
  181 AAATAAGAAAGTTATTTGTAAATATATTGTGACAGATCCTTTTGGGTTTTTTCATTTATG 
                                                                   
 
  241 GGGTTAATAAATTTATAGTGTATCAACATAAATTAATTTGTGTCAATTTACAGGAATGGT 
                                                                   
 
  301 TCCCCAAGGTGAGGCCAACTTTGCTCCATCTCTAAGCCCTGGGAGCTCCATGGTGCCGAT 
                   >>>>>>>>>>>>>>>>>>>>                            
 
  361 GCCAATCCCTCCTCCTCAGAGTTCTCTTCTCCAGCAAACTYCACCTGCCTCCGGGTATCA 
                                              *                  < 
 
  421 GTCACCAGACATGAAGGCCTGGCAGCAAGGAGCGATAGGAAACAACAAGTAAGGGGGCAG 
      <<<<<<<<<<<<<<<<<<<                                          
 
  481 TTTTTATATATGAGCATCCTTGATACTGTGATAAATCCTTGATACTGATAAATGCTACAG 
                                                                   
 
  541 TGGTTGAACCTCAGGAACATTATGTAAAGTGAAAGAAGGCCGGACACAAAAGGCCACATA 
                                                                   
 
  601 TGGCTACATTTATATGACGTTTCCCCGTTCCCCCGTTTATGTGTGGAGACAGAAAGCAGC 
                                                                   
 
  661 ACATAAGAACAGCCATGCTTTCATGGGCTGATTGTATTCACAGGCTAAGTAGAAGATTAT 
                                                                   
 
  721 TGGCTACTTCCATTTGCATAATGGAAAGAACTAAATTTTATATTATCAGCAAAGAAAAAT 
                                                                   
 
  781 GATTTTTAAATCTTATAAGTA 
                            
 
KEYS (in order of precedence): 
****** target 
>>>>>> left primer 
<<<<<< right primer 
 
For SNP rs2230782: 
    1 AATATCATGATTTCTCCTCGTAATCGTGGGAGTCCAAAGATAGCCTCACATCAGTTTTCT 
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   61 CCTGTTGCAGGTATTTGTGTTGACATTTCCTTTTATTTTTTTTCTTTTTAAGTAATTATT 
                                                                   
 
  121 CTTTCCATACTACTATAATTCTTGTAAAGTTAATCTATTTTATAATAGAAACTTTGAAGA 
                                                                   
 
  181 ATTAAGTTGTATTTTGTTACAGTGTCTGGTAGTCTAATTCTTTTCCTAAATTTTTTTTCA 
                                                                   
 
  241 AATTCAGGTGTGCACTCTCCCATGGCATCTTCTGGCAATACTGGGAACCACAGCTTTTCC 
                                                                   
 
  301 AGCAGCTCTCTCAGTGCCCTGCAAGCCATCAGTGAAGGTGTGGGGACTTCCCTTTTATCT 
                                                                   
 
  361 ACTCTGTCATCACCAGGCCCCAAATTGGATAACTCTCCCAATATGAATATTACCCAACCA 
                                                                   
 
  421 AGTAAAGTAAGCAATCAGGATTCCAAGAGTCCTCTGGGCTTTTATTGCGACCAAAATCCA 
                            >>>>>>>>>>>>>>>>>>>>>>>>                   
 
  481 GTGGAGAGTTCAATGTGTCASTCAAATAGCAGAGATCACCTCAGTGACAAAGAAAGTAAG 
                          *                                <<<<<<< 
 
  541 GAGAGCAGTGTTGAGGGGGCAGAGAATCAAAGGGGTCCTTTGGAAAGCAAAGGTCATAAA 
      <<<<<<<<<<<<<<<<<                                            
 
  601 AAATTACTGCAGTTACTTACCTGTTCTTCTGATGACCGGGGTCATTCCTCCTTGACCAAC 
                                                                   
 
  661 TCCCCCCTAGATTCAAGTTGTAAAGAATCTTCTGTTAGTGTCACCAGCCCCTCTGGAGTC 
                                                                   
 
  721 TCCTCCTCTACATCTGGAGGAGTATCCTCTACATCCAATATGCATGGGTCACTGTTACAA 
                                                                   
 
  781 GAGAAGCACCGGATTTTGCACAAGTTGCTGCAGAATGGGAATTCACCAGCTGAGGTAGCC 
                                                                   
 
  841 AAGATTACTGCAGAAGCCACTGGGAAAGACACCAGCAGTATAACTTCTTGTGGGGACGGA 
                                                                   
 
  901 AATGTTGTCAAGCAGGAGCAGCTAAGTCCTAAGAAGAAGGAGAATAATGCACTTCTTAGA 
                                                                   
 
  961 TACCTGCTGGACAGGGATGATCCTAGTGATGCACTCTCTAA 
                                                
 
KEYS (in order of precedence): 
****** target 
>>>>>> left primer 
<<<<<< right primer 
 
For SNP rs2076546: 
    1 TCCTGTGAATGCCACACGCACTGCTTACTGCTTCAGCCTCATTTTTACACAGAGTTACAC 
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   61 GAGAAATGCCCAGCTGGCAACCCAGTACCTCAATTATAGGGAATTCTCATTCTCTTTCAC 
                                                                   
 
  121 GTTTGCTTCTGTGCTCCAACTCTTTTCTAAACTACCCAATGCTGAGATTTTCTACAGAGT 
                                                                   
 
  181 CACAAAATAACACCCCACCTATTTTGAGTGCCATGAGAAACTTGTTCCATGGACAACATG 
                                                                   
 
  241 CCATCGGGCCAGGAACCCAGTTGGTTAGATGCTGCTGCTTGGCCATAGGGATTAGCCCCC 
                                                                   
 
  301 ATTCCCATGGGGATTTCACCAGGCCCTGGGGGAGCAAAAAGAAAGCACAAATTCTCAAAT 
                                                                   
 
  361 AAGAGCAAAAATTATCCTGAAACATCTAACTTTCTTTTTTCATGAAGAGGGGAGGGTGGA 
                                                                   
 
  421 CACTTACTCATTTGAAGCATCTGCTGCTGCTGTTGCAATACTGGTCTCGCACCTGGTATG 
                                        >>>>>>>>>>>>>>>>>>>>       
 
  481 CTATTAGACCGAAGAGGCAAYGTGGGAATAGAGCCACCCAGTGCAGGTCTGGGTAAAGAA 
                          *                                        
 
  541 GTATTATAATCTCCTCCTGGTCTTCCCATGGAGTTTGAATTCATAGGTTCCATTCTGCCG 
                        <<<<<<<<<<<<<<<<<<<<                       
 
  601 GCCTTTGAGTTTGGTAAGCCCCAGTCTCCTGAGGAAGGAGTCTGAGTCACAGTCACATTT 
                                                                   
 
  661 CGGTTTGGCCCACCTAAAACAGGTAGCCATACTTAGGTCTTTTCCATATTATAATGAAAT 
                                                                   
 
  721 CCTTCTTATACCATGTAAGTACAGCCATTATACACAACATCAACCTTGACAAAACAGCAC 
                                                                   
 
  781 TTTGTCATGGTAAGAAAAGGGCTGGCCAACTGTGGAGACATAGGCCACTATTCTCATATA 
                                                                   
 
  841 TTCAACAGGCTGGAAAATGTCATAGACCAAAAGACTCTTGAAGAGTTTACATAACCAAAA 
                                                                   
 
  901 CATAGAATAAATGAAGGATATTCATGGAAGAAACATACTAACGTTATTCAAAAAGTTATT 
                                                                   
 
  961 ATTTACTCCCAATTATTTAGATGGCTTTAAGTATTTTAAAT 
                                                
 
KEYS (in order of precedence): 
****** target 
>>>>>> left primer 
<<<<<< right primer 
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These are the results after performing HRM on the population for all the 3 
candidates SNPs. The genotyping results are divided into 2 tables, table 7.1 
represents the entire breast cancer sample and table 7.2 represents the matched 
control cases. Each sample has a unique sample number. As for the genotypes, 
“Homo” represents the wild type homozygous genotype and “Hetero” represents the 
heterozygous genotype. Any empty cell in the tables indicates that the sample 
couldn’t be reliably genotyped and have been omitted from analysis. 
Table 7.1. Genotyping Results of the Breast Cancer Cases for All Three 
Candidate SNPs. 
BC 
Cases rs1804645 rs2230782 rs2076546
Samples 
Numbers Genotypes 
BC0001 Hetero Homo Homo 
BC0002 Hetero Homo Homo 
BC0003 Hetero Homo Hetero 
BC0004 Hetero Homo Homo 
BC0005 Hetero  Homo 
BC0006 Hetero Homo Homo 
BC0007 Hetero Homo Homo 
BC0008 Hetero Homo Hetero 
BC0009 Hetero Homo Homo 
BC0010 Hetero Hetero Homo 
BC0011 Hetero Homo Homo 
BC0012 Hetero Homo Homo 
BC0013 Hetero Homo Homo 
BC0014 Hetero Homo Homo 
BC0015 Hetero Hetero Hetero 
BC0016 Hetero Homo Homo 
BC0017 Homo Homo Homo 
BC0018 Homo Hetero Homo 
BC0019 Homo Homo Homo 
BC0020 Homo Homo Hetero 
BC0021 Hetero Homo Homo 
BC0022   Homo Homo 
BC0023 Hetero Hetero Homo 
BC0024 Hetero Homo Homo 
BC0025 Homo Homo Homo 
BC0026 Hetero Homo Homo 
BC0027 Homo Homo Homo 
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BC0028 Homo Homo Hetero 
BC0029 Homo Homo Homo 
BC0030 Hetero Homo Homo 
BC0031   Homo Hetero 
BC0032 Homo Homo Homo 
BC0033 Homo Homo Homo 
BC0034 Homo Homo Homo 
BC0035 Homo Homo Hetero 
BC0036 Homo Homo Homo 
BC0037 Homo Homo Homo 
BC0038 Homo Hetero Homo 
BC0039 Homo Homo Homo 
BC0040 Hetero Homo Homo 
BC0041 Hetero Homo Homo 
BC0042 Hetero Homo Homo 
BC0043 Homo Homo Hetero 
BC0044 Homo Homo Homo 
BC0045 Homo Homo Homo 
BC0046 Hetero Homo Homo 
BC0047 Homo Homo Hetero 
BC0048 Hetero Homo Homo 
BC0049 Hetero Homo Homo 
BC0050 Homo Homo Homo 
BC0051 Homo Homo Homo 
BC0052 Hetero Homo Homo 
BC0053 Homo Hetero Homo 
BC0054 Homo Homo Homo 
BC0055 Homo  Homo 
BC0056 Hetero Homo Homo 
BC0057 Homo Homo Homo 
BC0058 Homo Homo Homo 
BC0059 Homo Hetero Homo 
BC0060 Homo Homo Homo 
BC0061 Homo Homo Homo 
BC0062 Homo Hetero Homo 
BC0063 Homo Homo Homo 
BC0064 Homo    
BC0065 Homo Homo Homo 
BC0066 Homo Homo Hetero 
BC0067 Homo Homo Homo 
BC0068 Homo Homo Homo 
BC0069 Hetero Hetero Homo 
BC0070 Homo Homo   
BC0071 Hetero Hetero Homo 
BC0072 Hetero Homo Homo 
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BC0073 Homo Homo Homo 
BC0074 Hetero  Hetero 
BC0075 Homo Homo Homo 
BC0076 Homo Hetero Homo 
BC0077 Homo Homo Homo 
BC0078 Homo Homo Homo 
BC0079 Homo Homo Hetero 
BC0080 Homo Homo Homo 
BC0081 Homo Homo Homo 
BC0082 Hetero  Homo 
BC0083 Homo Homo Homo 
BC0084 Homo Homo Homo 
BC0085 Homo Homo Hetero 
BC0086 Homo Homo Hetero 
BC0087 Homo Hetero Hetero 
BC0088 Homo Homo   
BC0089 Homo Homo Hetero 
BC0090 Homo Hetero Hetero 
BC0091 Homo Homo Homo 
BC0092 Hetero Homo Homo 
BC0093 Homo Homo Homo 
BC0094 Homo Homo Homo 
BC0095 Homo Homo Homo 
BC0096 Homo Homo Hetero 
BC0097 Homo Homo Homo 
BC0098   Homo Homo 
BC0099 Homo Homo Homo 
BC0100 Homo Homo Homo 
BC0101 Homo Hetero   
BC0102 Homo Homo   
BC0103 Homo Homo Hetero 
BC0104 Homo Homo Homo 
BC0105 Homo Hetero Homo 
BC0106 Homo Hetero Homo 
BC0107 Homo Hetero Homo 
BC0108 Homo Homo Homo 
BC0109 Homo Homo Homo 
BC0110 Homo Hetero Homo 
BC0111 Homo Homo Homo 
BC0112 Homo Homo Hetero 
BC0113 Homo Homo Homo 
BC0114 Hetero Homo Homo 
BC0115 Homo Homo Homo 
BC0116 Homo Hetero Homo 
BC0117 Homo Homo Homo 
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BC0118 Homo Hetero Homo 
BC0119 Homo Hetero Homo 
BC0120 Homo Homo   
BC0121 Hetero Homo Homo 
BC0122 Homo Hetero Homo 
BC0123 Homo Hetero Homo 
BC0124 control Control Control 
BC0125 Hetero Homo Homo 
BC0126 Hetero Hetero Homo 
BC0127 Hetero Homo Homo 
BC0128 Hetero Homo Homo 
BC0129 Homo Homo Homo 
BC0130 Homo Homo Homo 
BC0131 Homo Homo   
BC0133 Homo Homo Homo 
BC0134 Homo Homo Homo 
BC0135 Homo Homo Homo 
BC0136 Homo Homo Homo 
BC0137 Homo Homo   
BC0138 Hetero Homo Homo 
BC0139 Homo Homo Hetero 
BC0140 Homo Hetero Homo 
BC0141 Homo Homo Homo 
BC0142 Homo Homo Homo 
BC0143 Homo Homo Homo 
BC0144 Homo Hetero Homo 
BC0145 Hetero Homo Homo 
BC0146 Hetero Homo Homo 
BC0147 Homo Hetero Homo 
BC0148 Homo Homo Hetero 
BC0150 Homo Homo Homo 
BC0151 Homo Homo   
BC0152 Homo Homo Homo 
BC0153 Hetero Homo Hetero 
BC0154   Homo Homo 
BC0155   Homo Homo 
BC0156 Homo Homo Homo 
BC0157 Homo Homo   
BC0158 Hetero Homo Homo 
BC0159 Homo Homo Homo 
BC0160 Homo Homo Homo 
BC0161 Hetero Homo Homo 
BC0162 Homo Homo Homo 
BC0163 Homo Homo Homo 
BC0164 Homo Homo Homo 
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BC0165 Homo  Homo 
BC0166 Hetero Homo Homo 
BC0167 Hetero Homo Homo 
BC0168 Homo Homo Homo 
BC0169 Hetero Homo Hetero 
BC0170 Homo Homo Homo 
BC0171 Homo Homo Homo 
BC0172 Homo Homo Hetero 
BC0173 Hetero Homo Homo 
BC0175 Homo Hetero Homo 
BC0176 Homo Homo Homo 
BC0177 Homo Homo   
BC0178 Homo Hetero   
BC0179 Homo Homo Homo 
BC0180 Homo Homo Homo 
BC0181 Homo Homo Homo 
BC0182 Homo Homo Homo 
BC0183 Homo Homo Hetero 
BC0184   Homo Homo 
BC0185 Homo Homo Homo 
BC0186 Homo Homo Homo 
BC0187 Homo Homo   
BC0188 Hetero Homo Homo 
BC0189 Hetero Homo Homo 
BC0190 Homo Homo Homo 
BC0191 Homo Homo Homo 
BC0192 Homo Homo Homo 
BC0193 Homo Homo Homo 
BC0201 Hetero Homo Hetero 
BC0202 Hetero Homo Hetero 
BC0203 Hetero Homo Homo 
BC0204 Homo Homo Homo 
BC0205 Hetero Homo Homo 
BC0206 Homo Homo   
BC0207 Homo Homo Homo 
BC0208 Homo Homo Hetero 
BC0210 Homo Homo Homo 
BC0211 Homo Homo Homo 
BC0212 Homo Homo Homo 
BC0213 Homo Homo Homo 
BC0214 Homo Homo Homo 
BC0215 Homo Homo Homo 
BC0216 Homo Hetero Homo 
BC0217 Homo Homo Homo 
BC0218 Homo Homo Homo 
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BC0219 Hetero Hetero Homo 
BC0220 Homo Homo Homo 
BC0221   Homo Homo 
BC0222 Hetero Homo Homo 
BC0223 Homo Homo Homo 
BC0224   Homo Homo 
BC0225 Homo Hetero Homo 
BC0226   Homo   
BC0227 Homo Hetero Homo 
BC0228 Homo Homo Homo 
BC0229 Homo Homo Homo 
BC0230 Homo Homo Homo 
BC0231   Homo Homo 
BC0232 Homo Homo Homo 
BC0233 Homo Homo Homo 
BC0234   Homo   
BC0235 Hetero Homo Homo 
BC0236   Hetero Homo 
BC0237 Hetero Hetero Homo 
BC0238 Hetero Homo Homo 
BC0240   Homo Homo 
BC0241   Homo Homo 
BC0242   Homo   
BC0243 Homo Homo Homo 
BC0244 Homo Homo Hetero 
BC0245   Homo Homo 
BC0268 Homo Homo Hetero 
BC0269 Homo Homo Homo 
BC0270 Homo Homo Homo 
BC0271 Homo Homo Homo 
BC0272 Homo Homo Homo 
BC0273 Homo Homo Homo 
BC0274 Homo Homo Hetero 
BC0275 Homo Homo Homo 
BC0276 Homo Homo Homo 
BC0277 Homo Hetero Homo 
BC0278 Homo Homo Homo 
BC0279 Homo Homo Homo 
BC0280 Homo Homo Homo 
BC0281 Hetero Homo Homo 
BC0282 Homo Homo Homo 
BC0283 Homo Homo   
BC0284 Homo Homo Homo 
BC0285 Hetero Homo Homo 
BC0286 Hetero Homo   
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BC0287 Homo Homo Homo 
BC0288 Homo Homo   
BC0294 Hetero Homo Homo 
BC0295 Homo Homo Homo 
BC0297   Homo Homo 
BC0298 Homo Homo Homo 
BC0311 Homo Homo Homo 
BC0312 Homo Hetero Homo 
BC0313 Homo Homo Homo 
BC0314 Homo Homo Homo 
BC0315 Hetero Homo Homo 
BC0316 Homo Homo Homo 
BC0317 Homo Hetero Homo 
BC0319 Homo Hetero Homo 
BC0320   Hetero   
BC0321 Homo Hetero Homo 
BC0322 Homo Hetero Homo 
BC0323 Homo Homo Homo 
BC0324 Homo Homo Hetero 
BC0325 Homo Homo Homo 
BC0326 Homo Hetero Homo 
BC0327 Homo Hetero Homo 
BC0328   Homo   
BC0329 Homo Homo Homo 
BC0331 Homo Homo Homo 
BC0332 Homo Homo Homo 
 
Table 7.2. Genotyping Results of the Control Cases for All Three Candidate 
SNPs. 
Controls rs1804645 rs2230782 rs2076546
Samples 
Numbers Genotypes 
mu042 Homo Homo Homo 
Gn82   Homo   
n68 Homo Homo Homo 
mu458 Hetero Hetero Homo 
mu565 Homo Homo Homo 
a62 Homo Homo Hetero 
n36 Homo Homo Homo 
mu616 Homo Homo Homo 
mu507 Hetero Homo Homo 
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mu551 Homo Hetero Homo 
n55 Homo Homo Homo 
n85   Homo Hetero 
mu158 Homo Homo Homo 
mu281 Homo Homo Homo 
a03 Homo Hetero Homo 
n38 Homo Homo Homo 
n17      
c8062 Homo Homo Homo 
mu352 Hetero Homo   
n27 Homo Homo Homo 
n42 Homo Homo Homo 
n13 Homo Homo Homo 
g92 Homo Homo Homo 
n89 Homo Homo Homo 
mu460   Homo Homo 
n20 Hetero Homo Homo 
mu516 Homo Hetero Homo 
mu573 Homo Homo Homo 
n76   Homo Homo 
mu472 Homo Homo Homo 
n23   Homo Homo 
mu147      
mu470   Homo Homo 
mu282 Homo Homo Hetero 
mu612    Homo 
mu236 Homo Homo Homo 
mu145 Homo Homo Homo 
mu558 Homo Homo Homo 
mu564 Homo Homo Homo 
Gn477 Homo Hetero Homo 
n06 Homo Hetero Hetero 
n28      
mu638 Homo Homo Homo 
mu911 Hetero Homo Hetero 
mu234 Homo Homo Homo 
mu453 Homo Homo   
n73 Homo Hetero   
water      
mu125 Homo Homo   
mu289 Homo Homo Homo 
mu135   Hetero   
mu506   Hetero   
mu268 Homo Homo Homo 
c8545 Homo Homo Hetero 
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mu112 Homo Homo Homo 
n46 Hetero Homo   
c8588 Homo Homo Homo 
mu591 Homo  Homo 
mu118 Homo Homo   
a47 Homo Homo Hetero 
mu117 Homo Homo   
a32   Homo   
mu138 Homo Homo Homo 
mu480 Hetero Hetero Homo 
mu203   Homo   
g63 Homo Homo Homo 
c8208 Hetero Homo Homo 
a58   Homo Homo 
mu493 Homo Homo   
a16   Homo   
mu102 Homo Homo Homo 
mu492 Homo Homo Hetero 
mu508 Hetero Homo Homo 
c8331 Homo Homo Homo 
mu426 Hetero Homo   
n77 Homo Homo Homo 
mu457 Homo Homo Homo 
mu190 Homo Homo Homo 
mu215 Homo Homo Homo 
n92/ 
ht015 Homo Homo Homo 
n26 Homo Homo Homo 
a66 Homo Homo Homo 
mu497 Homo Homo Homo 
mu070 Homo Homo Homo 
c8206 Homo Homo   
c8219 Homo Homo Homo 
n35      
mu005 Hetero Homo Homo 
c8583 Homo Homo Homo 
mu602 Hetero Homo Homo 
mu511 Homo Homo Hetero 
n90   Homo Homo 
mu532 Homo Homo Homo 
a11 Homo Homo Homo 
c8249 Homo Homo Homo 
c8436 Homo Homo Homo 
n51 Homo Homo Homo 
mu490 Homo Homo Homo 
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mu154   Homo Hetero 
n44 Homo Homo Homo 
c8150   Homo   
mu270 Hetero Homo Homo 
mu584 Hetero Homo Homo 
mu653 Hetero Hetero Homo 
Mu2471 
(mu266) Homo Homo Homo 
mu137 Homo Homo Homo 
mu248 Homo Homo Homo 
mu487 Homo Homo Homo 
mu535 Homo Homo Homo 
mu346 Homo Homo Homo 
mu637 Homo Homo Homo 
mu670   Homo   
mu600 Homo Homo Homo 
a30 Homo  Homo 
a05 Homo Homo Homo 
n65 Homo Hetero Homo 
mu243 Homo Homo Homo 
mu119 Homo Homo flipped 
mu195 Homo Homo Homo 
C8865 
(c8167) Homo Homo Homo 
mu510 Homo Homo Homo 
n41 Homo Homo Homo 
n57 Hetero Hetero Homo 
mu547 Hetero Homo Hetero 
n11 Homo Hetero Homo 
c8247 Homo Homo Hetero 
g98 Homo Homo Homo 
mu454 Homo Homo Homo 
mu208 Homo Homo Homo 
gn91 Homo Homo Homo 
mu065 Homo Homo Hetero 
n48 Homo Hetero Homo 
mu474 Hetero Hetero   
mu271 Hetero Homo Homo 
a41 Hetero Homo Homo 
mu290 Homo Homo Homo 
c8171 Homo Homo Homo 
c8155 Hetero Homo Homo 
mu447 Homo Homo Homo 
mu442 Homo Homo Homo 
mu343 Homo Homo   
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mu341 Homo Homo Homo 
water      
c8319 Homo  Homo 
n04 Homo Hetero Homo 
mu120 Homo Hetero Homo 
c8173 Homo Hetero Homo 
mu672 Homo Homo   
mu338 Homo Homo Homo 
Mu1371 Homo Homo Homo 
mu349 Hetero Homo Hetero 
Mu2311 Hetero Homo Homo 
c8204 Homo Homo Homo 
Gn148 Hetero Homo Homo 
Gn764 Homo Hetero Homo 
Mu1814 Homo Homo Homo 
Gn514 Homo Homo Homo 
c8236 Homo Homo Homo 
c8022 Hetero Homo Homo 
Gn110 Homo Homo Homo 
Gn389 Homo Hetero Homo 
c8165 Homo Homo Homo 
Gn382 Homo Hetero Homo 
c8174 Homo Homo   
c8194 Homo Homo Homo 
c8309    Homo 
c8128   Homo Hetero 
c8015 Homo Homo Homo 
c8140 Homo Homo Homo 
c8345 Homo Homo Homo 
c8046 Homo Homo Homo 
c8116 Homo Homo Homo 
c8281 Homo Hetero Homo 
c8172 Homo Homo Homo 
c8191 Hetero Homo Homo 
Mu2049 Homo Hetero Homo 
Mu639 Homo Homo Homo 
Mu644 Homo Homo Hetero 
Gn686 Homo Homo Homo 
Gn251 Homo Homo Homo 
c8419 Homo Homo Hetero 
Mu1791   Homo Homo 
c8050 Homo  Homo 
Gn898 Homo Homo Hetero 
c8131 Homo Homo Homo 
c8536   Homo Hetero 
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c8105 Homo Hetero Homo 
Gn134 Homo Homo Homo 
Gn401 Homo Homo Homo 
Mu1844 Homo Homo Homo 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
CC0001 Homo Homo Homo 
CC0002 Hetero Homo Homo 
CC0004 Homo Homo Homo 
CC0006 Homo Homo Homo 
CC0012 Homo Homo Homo 
CC0013 Homo Homo Homo 
CC0014   Homo Homo 
CC0015 Homo Homo Homo 
CC0017 Homo Homo Homo 
CC0019 Homo Homo Homo 
CC0020 Homo Hetero Homo 
CC0024 Homo Homo Homo 
CC0026 Homo Homo Homo 
CC0027 Homo Homo Homo 
CC0033 Homo Homo Homo 
CC0040 Homo Homo Homo 
CC0041 Homo Homo Homo 
CC0052 Hetero Homo Homo 
CC0053 Homo Homo Homo 
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CC0057 Homo Homo Hetero 
CC0060 Homo Homo Homo 
CC0062   Homo Homo 
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Appendix G 
Results 
This T-test was  performed on SPSS program: 
Independent Samples Test
 Levene's Test for 
Equality of 
Variances
t-test for Equality of Means 
F Sig. t df Sig. (2-
tailed) 
Mean 
Differen
ce 
Std. 
Error 
Differen
ce 
95% Confidence 
Interval of the 
Difference
Lower Upper
BMI 
Equal 
variances 
assumed 
.410 .523 2.01
0
178 .046 1.37305
90
.683079
5 
.025083
0
2.72103
50
Equal 
variances not 
assumed 
  2.00
9
173.
296
.046 1.37305
90
.683500
0 
.024002
5
2.72211
55
Menarc
he 
Equal 
variances 
assumed 
.254 .615 .244 181 .808 .05846 .23973 -.41456 .53148
Equal 
variances not 
assumed 
  .247 177.
668
.806 .05846 .23711 -.40946 .52638
Breastfe
eding 
Equal 
variances 
assumed 
.998 .319 -
1.06
6
179 .288 -.244 .229 -.696 .208
Equal 
variances not 
assumed 
  -
1.04
5
151.
718
.298 -.244 .234 -.706 .218
Pregnan
cies 
Equal 
variances 
assumed 
2.279 .133 -.646 183 .519 -.180 .279 -.732 .371
Equal 
variances not 
assumed 
  -.630 152.
938
.529 -.180 .286 -.746 .385
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